

---

# INDEX

---

Page references followed by t indicate material in tables.

- AAAV vaccinations, 100
- Acceptors, in carbohydrate synthesis, 17, 18
- ACE1* gene, in yeast-based vaccine vector design, 142
- Actin-polymerizing (ActA) protein, *Listeria monocytogenes* and, 116, 117
- Activated T cells
- CD137 on, 256–257
  - PD-1 expression on, 249
- Activation-induced cell death (AICD). *See also* Apoptosis
- anti-CD137 and, 255, 260
  - in cancer vaccine evaluation, 300
- Active immunization, as cancer immunotherapy strategy, 230–231
- Acute myeloblastic leukemia (AML), CD137L and, 254
- Adaptive immune responses, in immune monitoring, 273
- Adaptive immunity
- carcinogenesis and, 229
  - coupling yeast-based cancer immunotherapy with, 131–149
  - CpG ODNs in stimulating, 47–49
  - in immune rejection of solid tumors, 51–52
- Adaptor molecules, CpG ODNs in stimulating, 47
- Adenocarcinoma, BCG versus, 36
- Adenomatous polyposis coli (APC) protein, in yeast-based immunotherapy, 135, 146
- Adenoviruses
- in CD137 studies, 258
  - as gene therapy vehicles, 95–96
- Adenovirus LIGHT-expressing vectors (Ad-LIGHT), treatment of metastases and, 235–236
- ADHI* (alcohol dehydrogenase) promoter, in yeast-based vaccine vector design, 142
- Adjuvants, 4–6. *See also* Biological adjuvants
- in cancer vaccines, 296
  - CpG ODNs as, 47, 48, 49
  - CpG ODN synergy with, 50
  - human clinical trials with CpG ODNs, 50–51, 51–53
  - Listeria monocytogenes* as, 114
  - in mouse tumor models, 51
  - safety of, 53–54
  - yeasts as, 132
- Administration route, in yeast-based immunotherapy, 143–144
- Adoptive T cell immunotherapy, 3
- in immune monitoring, 272
- Adoptive T cell transfer therapy, as cancer immunotherapy strategy, 217–218, 230–231
- Adult T cell lymphoma/leukemia, CD25 antibodies versus, 191
- Ag104A immunity, in CD137 studies, 257
- Ag104L<sup>d</sup>-LIGHT tumor cell line, creating tumor lymphoid tissue and, 233–234
- Age, in vaccine evaluation, 292
- Allogeneic cell lines, 155
- Allogeneic HSCT, 218–219
- immunotherapy and, 9
  - T cell depletion and, 219–220
- Allogeneic vaccines, 8
- modification to secrete cytokines, 157–159
  - tumors and, 155s
  - whole-cell, 153–157
- Alloimmune response, 8
- Allospecific response, 8

---

## *Cancer Vaccines and Tumor Immunity*

Edited by Rimas Orentas, James W. Hodge, and Bryon D. Johnson  
Copyright © 2008 John Wiley & Sons, Inc.

- Alphaviruses, as cancer-therapy vaccine vectors, 96
- ALVAC canarypox vector, in cancer therapy, 96–97, 98t
- American Urological Association (AUA) guidelines, for BCG, 32
- Amino acid sequences, flanking, 71–72
- Anastrozole, in endocrine therapy, 174
- Androgen ablation, in endocrine therapy, 175
- Androgen signaling, 223
- Angiogenesis, inside tumors, 234–235
- Animal studies, of BCG in prostate cancer treatment, 36
- Animal tumor models, in yeast-based immunotherapy, 135–137. *See also* Mice
- Anthracycline, clinical trials of, 219
- Antibiotic resistance, during BCG treatment, 38
- Antibiotics, safety concerns related to, 123
- Antibodies (Abs), 23. *See also* IgG antibodies; IgM antibodies
- bacterial vaccine vectors and, 114
  - in CD137 studies, 257
  - in evaluating immune competence, 296
  - inside tumors, 234
  - vaccine activation of, xiii
- Antibody-dependent cellular cytotoxicity (ADCC)
- in endocrine therapy, 174
  - in monoclonal antibody therapy, 173
- Antibody therapy, 3
- immunotherapy and, 8
- Antibody titers, in immune monitoring, 273
- Anticancer vaccines, investigation of, xiii–xiv
- See also* Antitumor vaccines; Cancer vaccines; Vaccine entries
- Anti-CD3 antibody
- in CD137 studies, 258, 259–260
  - PD-1/B7-H1/B7-DC pathway and, 248
  - PD-1 gene and, 245
- Anti-CD28 antibody
- in CD137 studies, 260–261
  - PD-1/B7-H1/B7-DC pathway and, 247–248
- Anti-CD137 antibody
- CD137 and, 255, 260–261
  - PD-1/B7-H1/B7-DC pathway and, 253
- Anti-CD137L antibody, in CD137 studies, 258
- Anti-CD137 mAbs, CD137L and, 255
- Anti-CTLA4 antibodies. *See also* Cytotoxic T lymphocyte antigen 4 (CTLA4)
- PD-1/B7-H1/B7-DC pathway and, 248
  - Tregs and, 193
- “Antigen cascade,” xiv
- Antigen delivery, in yeast-based immunotherapy, 146
- Antigen escape variants, xiv
- Antigen exposure postimmune depletion, 220–223
- Antigen expressed, in yeast-based immunotherapy, 143
- Antigen-expressing dendritic cells, strategies for increasing, 82–83
- Antigenic heterogeneity, of tumors, xiv
- Antigenic profile, allogeneic vaccines and, 155
- Antigen–molecule linkage, in increasing antigen-expressing DCs, 83
- Antigen-presenting cells (APCs), 8
- in antigen-specific therapy, 6
  - bacterial vaccine vectors and, 114
  - CD137L on, 254, 255
  - costimulatory molecules and, 244
  - CTL activation and, 70
  - in ELISpot assay, 275
  - immune-response induction and, 100, 101
  - in treating HPV, 80–81, 87
  - whole-cell vaccines and, 154, 160
  - in yeast-based immunotherapy, 132, 133
- Antigens. *See also* Human leukocyte antigen (HLA) types; Target antigens; Yeast-delivering tumor antigens
- carcinogenesis and, 229–230
  - CpG ODN coadministered with, 49
  - in immune monitoring, 271
  - passenger, 114
  - in pDC depletion, 195
  - in polyvalent vaccines, 22
  - tumor-associated, xv
  - tumor-associated carbohydrate, 16
  - in unimolecular multivalent vaccines, 23–25
- Antigen-specific adaptive immune responses, innate immune system in, 49
- Antigen-specific assays, in cancer vaccine evaluation, 300, 301, 304
- Antigen-specific cancer immunotherapy
- defined, 79–80
  - HPV-associated cervical cancer as model system for, 79–94
- Antigen-specific responses, CpG ODN–induced, 49
- Antigen-specific T cells
- in antigen-specific cancer immunotherapy, 79–80, 81
  - in immune monitoring, 272
  - LMP polyepitopes and, 74, 75, 76
  - stroma and, 230
  - in tetramer analysis, 276
  - tumor regression and, 231
- Antigen-specific therapy, peptide and protein antigens in, 6–7

- Anti-GITR antibodies, versus Tregs, 192–193.  
*See also* Glucocorticoid-induced tumor necrosis factor receptor (GITR)
- Anti-human papilloma virus antibody titers, in immune monitoring, 272
- “Anti-TLR9” antibodies, 45
- Antitumor immune response. *See also* Antitumor response  
 CD137 and, 255–256, 257–258  
 as goal of cancer immunotherapy, 229–230  
 intratumor generation of, 229–242  
 PD-1/B7-H1/B7-DC pathway and, 253  
 tumor cells and, 171
- Antitumor immunity, generation of, xiii, xvi
- Antitumor response, strategies for activating, xiii–xiv. *See also* Antitumor immune response
- Antitumor vaccines. *See also* Anticancer vaccines; Cancer vaccines; Vaccine entries  
 carbohydrate-based, 15–27  
 evaluation of, 291–307
- Apoptosis. *See also* Activation-induced cell death (AICD); PD-1 (programmed death 1) gene  
 breast tumor vaccines and, 171, 172  
 in evaluating immune competence, 297, 304  
 PD-1 gene and, 245
- Aromatase inhibitors, in endocrine therapy, 174
- Artificial APC (aAPC), in CD137 studies, 260–261
- Assays  
 in cancer vaccine evaluation, 295, 297–301  
 in cancer vaccine use, 10  
 in immune monitoring, 273–274, 284–285, 295  
 QA/QC program for, 301–303, 304
- Assay validation, 284  
 quality assurance/quality control for, 303
- Augustine, Matthew, ix, 243
- Autoimmune disease, cancer immunity suppression and, 211
- Autoimmune pathogenesis, PD-1/B7-H1/B7-DC pathway and, 246, 248
- Autoimmune responses, PD-1/B7-H1/B7-DC pathway and, 246
- Autoimmunity, cancer immunotherapy strategies and, 231–232
- Autologous DCs, in ELISpot assay, 275
- Autologous HSCT  
 animal models of, 206  
 future of, 214  
 immune reconstitution following, 206–210  
 immune regulatory cells and, 211–212, 213  
 immunotherapy and, 9  
 tumor burden and, 212–213  
 tumor vaccination following, 205–215
- Autonomously regulated sequence (ARS), yeast-based vaccine vector design and, 140
- Auxotrophies, yeast-based vaccine vector design and, 140
- Avipox virus, boosts for, 100
- B7-1/CD80 costimulatory molecules, 157
- B7-1 costimulatory molecule  
 in combination therapies, 103  
 immune-response induction and, 100, 101
- B7/CD28/CTLA4 pathway, 261–262  
 costimulatory and coinhibitory molecules and, 244
- B7-DC ligand  
 functions of, 246, 247–248  
 PD-1/B7-H1/B7-DC pathway and, 245–247, 251, 252, 253  
 structure of, 246–247
- B7-H1 ligand  
 functions of, 246, 247, 248–249  
 PD-1/B7-H1/B7-DC pathway and, 245–247, 251, 252, 253  
 structure of, 245–246, 246–247
- B7-H1 molecule, mDCs and, 195–196
- B7-H4<sup>+</sup> myeloid cells, 197
- B16/D5 melanoma tumor, in CD137 studies, 261
- Bacillus Calmette–Guérin (BCG), xiv, 8  
 as adjuvant, 5  
 allogeneic vaccines and, 156  
 chemotherapy versus, 32–33  
 combination immunotherapy using, 35  
 disease progression and, 34–35  
 in genitourinary cancer immunotherapy, 29–42  
 immunotherapy technique using, 31–32  
 improving immunotherapy using, 35  
 in situ bladder carcinoma treatment using, 33–34  
 maintenance, 34–35  
 mortality and, 34–35  
 toxicity of, 37–38
- Bacteria  
 in antigen-specific therapy, 7, 113–129  
 recombinant antigen expression in, 121
- Bacterial CpG DNA, in adjuvants, 5–6
- Bacterial lipopolysaccharide (LPS), in yeast-based immunotherapy, 134
- Bacterial vaccine vectors, 114  
 safety concerns related to, 123
- Barnett, Brian G., ix, 189
- Basiliximab, versus CD25, 191
- Batching  
 in cancer vaccine evaluation, 298  
 quality assurance/quality control in, 303

- B cell lymphoma, PD-1/B7-H1/B7-DC pathway and, 251
- B-cell-mediated IgM response, 16. *See also* Immunoglobulin M (IgM)
- B cells. *See also* B lymphocytes  
CpG ODNs and, 49  
PD-1/B7-H1/B7-DC pathway and, 246  
PD-1 expression on, 246  
in stimulating innate and adaptive immunity, 47–48
- BCG antigens, 37
- Becacizumab, in monoclonal antibody therapy, 174
- $\beta$  cells, PD-1/B7-H1/B7-DC pathway and, 248
- $\beta$ -glucan receptor, in yeast-based immunotherapy, 133
- Bioanalytical Method Validation, 303
- Biofection, with *Listeria monocytogenes*, 119
- Biological adjuvants, for immune system activation, xiv. *See also* Adjuvants
- Biologic vectors  
in antigen-specific therapy, 7, 113–129, 131–149  
safety concerns related to, 122–123
- Bioluminescent imaging (BLI), in vivo imaging via, 283
- Biomarkers, in cancer vaccine evaluation, 304
- Biphosphonate therapy, clinical trials of, 219
- Bladder cancer, bacillus Calmette–Guérin in treatment of, 29–30, 31–35, 38
- Blood handling, vaccine production and, 293
- B lymphocytes, CD137 mRNA in, 253–254. *See also* B cell entries
- Bone marrow (BM)  
autologous HSCT and, 206–207, 208, 209  
cancer immunity suppression and, 211, 213  
CD137L and, 254–255
- Bone marrow transplantation, 3  
immunotherapy and, 9
- Boosts  
for intracellular bacteria-based vaccines, 121  
for poxvirus vaccines, 100
- Borges, Virginia, ix, 131
- Breast cancer, 169  
application of polyepitope technology to, 74t, 76  
globo-H-KLH conjugate and, 18–19  
human clinical trials of GM-CSF-secreting vaccines in, 178  
*Listeria monocytogenes* versus, 118  
treatment of, 217
- Breast cancer cells, costimulatory-molecular whole-cell vaccine modification and, 157
- Breast cancer therapeutics, jump-starting tumor immunity with, 169–187
- Breast cancer treatment, clinical trials of, 219
- Breast cancer vaccines, 170  
combined with standard cancer therapeutics, 170
- Breast tumor immunity, 169–187  
barriers to, 170  
chemotherapy and, 170–173  
endocrine therapy and, 173, 174–175  
monoclonal antibody and, 173–174  
*neu* transgenic mouse model and, 175–178  
novel immune-based therapies and, 178–180
- Breast tumor vaccine, 8
- Brewer's yeast, in immunotherapy, 131–132, 145–147. *See also* *Saccharomyces cerevisiae*
- Brumlik, Michael J., ix, 189
- Bulk assays, in cancer vaccine evaluation, 297, 298
- Calmette, Albert, 30
- Canada, BCG treatment in, 38
- Canarypox vector (ALVAC), in cancer therapy, 96–97, 98t
- Cancer, 79. *See also* Breast cancer entries; Carcino- entries; Melanoma entries; Metastases; Ovarian cancer; Prostate cancer; Solid tumors; Tumor entries  
bacillus Calmette–Guérin in treatment of, 30–31  
chemokines and, 194  
GI-4000-01 phase I safety and immunogenicity in, 145  
GI-4000-02 phase II testing in, 145  
immune system and, 4  
*Listeria monocytogenes* in therapies versus, 113–129  
Cancer–antigen–specific response, 8  
Cancer immunity suppression, Tregs in, 211–212, 213  
Cancer immunotherapy, 79–80. *See also* Antigen-specific cancer immunotherapy; Antigen-specific therapy; Immunotherapy entries  
antitumor immune response as goal of, 229–230  
costimulatory molecules in, 243–268  
current strategies for, 230–231  
history of, 243–244  
*Listeria monocytogenes* in, 113–129  
new paradigms in, xiii–xvi  
vaccines in, xiii, 95, 205–206  
Cancer treatment, 224

- Cancer type, in vaccine evaluation, 292
- Cancer vaccines
- administration of, xiv–xv
  - advances in immune monitoring strategies for, 271–289
  - in antigen-specific therapy, 6–7
  - as cancer immunotherapy strategy, 230–231
  - carbohydrate-based, 15–27
  - cell-based, 7–10
  - clinical activity of, xiv
  - in combination therapy, xv, xvi
  - defined, 4
  - defining effective responses to, 10–11
  - enhancing by stimulating TLR9, 43–66
  - immune evaluation of, 291–307
  - immune monitoring assays for, 273–274, 284–285
  - new paradigms in, xiii–xvi
  - objectives of, 295–296
  - poxviral vectors for, 95–111
  - pre-administration immune competence evaluation of, 296–297
  - promise of, 3–11
  - tools necessary to support, 292–295
  - tumor burden and, 212–213
- Candida*, yeast-based immunotherapy and, 133
- Canvaxin, allogeneic vaccines and, 156
- Carbohydrate-based antitumor vaccines, 15–27
- future directions in, 25–26
- Carbohydrates
- synthesis of, 16–18
  - of tumor cell surfaces, 15–16
- Carboxyfluorescein diacetate (CFSE), in T cell proliferation assays, 282
- Carcinoembryonic antigen (CEA)
- in antigen-specific therapy, 6, 97
  - in combination therapies, 102–103
  - with MVA, 104–105
  - in yeast-based immunotherapy, 135, 138
- Carcinogenesis, genetic changes associated with, 229–230
- Carcinoma in situ (CIS), BCG treatment of, 33–34
- Carrier molecules, immunogenic, 16
- CCL22 tumor-secreted chemokine, 194
- CCR4 receptor, CCL22 chemokine and, 194
- CD3, in CD137 studies, 260–261
- CD3<sup>+</sup>CD8<sup>+</sup> tetramer<sup>+</sup> cells, in tetramer analysis, 277
- CD4<sup>+</sup>CD25<sup>+</sup> Tregs, 197–198
- in immune monitoring, 272–273
  - inside tumors, 234
  - mDCs and, 196
  - monoclonal antibodies versus, 190–191
  - Ontak versus, 191–192
  - TAA-specific, 197, 198
  - in tetramer analysis, 277
- CD4<sup>+</sup>Foxp3<sup>+</sup> T cells, cancer immunity suppression and, 211, 212
- CD4<sup>+</sup> T cell responses, CpG ODNs in stimulating, 53
- CD4<sup>+</sup> T cells. *See also* Effector CD4<sup>+</sup> T cells; Helper CD4 T cells; T-regulatory (Treg) activity
- in cancer vaccine evaluation, 299
  - CD137/CD137L in, 254, 255, 256–257
  - in CD137 studies, 257, 259
  - in chemotherapy-modulated immune tolerance, 171, 172
  - cytokine-secreting tumor cells and, 158
  - in ELISpot assay, 275
  - enhancing DC antigen expression via, 84, 86
  - in flow cytometry, 278
  - following syngeneic HSCT, 209, 210
  - GM-CSF-secreting vaccines and, 176, 177
  - in immune-based therapies, 179
  - in increasing antigen-expressing DCs, 83
  - inside tumors, 234
  - PD-1/B7-H1/B7-DC pathway and, 248, 249, 250, 251
  - regeneration following HSCT, 220–223
  - in treating HPV, 80–81
  - vaccine activation of, xiii
  - whole-cell vaccines and, 154
- CD4<sup>+</sup> Tregs, 190
- CD25 and, 191
- CD8<sup>+</sup> T cell responses
- CpG ODNs in stimulating, 48, 51, 53
  - LMP polyepitopes and, 75
  - toll-like receptors and, 44
  - in yeast-based immunotherapy, 134–135, 146
- CD8<sup>+</sup> T cells. *See also* Effector CD8<sup>+</sup> T cells
- Ad-LIGHT administration and, 236
  - in cancer vaccine evaluation, 298, 299
  - CD137/CD137L in, 255, 256–257
  - in CD137 studies, 259, 261
  - in chemotherapy-modulated immune tolerance, 171, 172
  - in clinical trials of DNA-based vaccines, 87
  - costimulatory-molecular whole-cell vaccine modification and, 157
  - in cytotoxic assays, 282
  - in ELISpot assay, 275
  - in enhancing DC antigen presentation, 86
  - in enhancing DC–T cell interaction, 86
  - following syngeneic HSCT, 209, 210

- CD8<sup>+</sup> T cells (*Continued*)  
 in flow cytometry, 278  
 GM-CSF-secreting vaccination and  
 monoclonal antibody therapy and,  
 177–178  
 in immune-based therapies, 179  
 in increasing antigen-expressing DCs, 82, 83  
 inside tumors, 234, 235  
 in microarray analysis, 280  
 PD-1/B7-H1/B7-DC pathway and, 249–250,  
 251, 252  
 pDC interactions with, 195  
 regeneration following HSCT, 221–223  
 in tetramer analysis, 277  
 in treating HPV, 80–81  
 vaccine activation of, xiii  
 whole-cell vaccines and, 154
- CD8<sup>+</sup> Tregs, 197
- CD25  
 monoclonal antibodies versus, 190–191  
 Ontak versus, 191–192
- CD25<sup>+</sup> T cells, 190–191, 191–192  
 cancer immunity suppression and, 211, 213
- CD28, CD137 and, 256, 259–260, 261
- CD28 gene, PD-1/B7-H1/B7-DC pathway and,  
 245
- CD28-independent costimulation, creating tumor  
 lymphoid tissue and, 234
- CD36 scavenger receptor, in yeast-based  
 immunotherapy, 133
- CD44<sup>hi</sup> memory T cell response,  
 GM-CSF-secreting vaccines and, 177
- CD45RA isoform phenotype, 221
- CD137/CD137L pathway, 253–261, 261–262  
 costimulatory and coinhibitory molecules and,  
 244
- CD137/Fc fusion protein construct, 254, 255
- CD137L (CD137 ligand)  
 identification of, 254  
 structure of, 254
- CD137L expression, 258–259
- CD137L gene, 254
- CD137 mRNA, 253–254
- CD137 protein  
 binding partners for, 254  
 structure of, 253
- cDNA, in microarray analysis, 280
- Cell-based cancer vaccines, 7–10
- Cell Genesys, Incorporated, 181
- Cell-surface carbohydrate epitopes, clustered  
 vaccines and, 21
- Cell-surface carbohydrates, of tumor cells, 15–16
- Cell surface glycoprotein molecules, APCs and,  
 244
- Cellular vaccines, support for, 293
- CEM cell line, CD137 mRNA in, 253
- Centromeric DNA elements (CENs), yeast-based  
 vaccine vector design and, 140
- Cervical cancer, 80  
 as antigen-specific cancer immunotherapy  
 model system, 79–94  
 application of polyepitope technology to, 74t,  
 76  
 human papillomavirus and, 80  
*Listeria monocytogenes* versus, 117–118
- Cetuximab, in monoclonal antibody therapy, 174
- cGMP (current good manufacturing practices)  
 vaccine generation, support for, 292–293
- Chemistry manufacturing and controls (CMC)  
 section, safety of yeast-based therapeutics  
 and, 144–145
- Chemokines, 194  
 in creating tumor lymphoid tissue, 232
- Chemokine signaling, versus Tregs, 194
- Chemotherapeutic drugs, antitumor immunity  
 and, xiii
- Chemotherapy, 224. *See also* High-dose therapy  
 BCG versus, 32–33  
 breast tumor immunity and, 170–173  
 breast tumor vaccines and, 171  
 dose-intensive, 218–219  
 GM-CSF-secreting vaccines and, 176–177  
 immune-depleting, 217–218  
 immune tolerance modulation via, 171–172  
 immunotherapy and, 8, 9, 10  
 poxvirus vectors in combination with, 102,  
 103–104  
 tumor microenvironment and, 173
- Chen, Lieping, ix, 229
- Chloramphenicol transferase genes, 120
- Chronic lymphocytic leukemia, fludarabine  
 versus, 192
- Chronic myelogenous leukemia (CML) patients,  
 HSCT and, 218
- Class II-associated Ii peptide (CLIP), in  
 enhancing DC antigen presentation, 85, 86
- Class A CpG ODNs, 46
- Class B CpG ODNs, 46–47  
 regulatory T cells and, 48
- Class C CpG ODNs, 46
- Clinical responses, effective, 10–11
- Clinical studies/trials, xiv, xv, xvi, 3–4  
 of allogeneic vaccines, 155–156  
 of alternatives to high-dose chemotherapy,  
 219–220  
 of bacillus Calmette–Guérin, 31, 32–33,  
 34–35  
 of breast cancer treatments, 219

- of breast cancer vaccines, 170
- of cancer immunotherapy strategies, 230–231
- of cancer vaccines, xv
- of clustered vaccines, 21–22
- of combination therapies, 102–104
  - with CpG ODNs, 50–51, 51–53
- in DNA vaccine development, 86–87
- of globo-H-KLH conjugate, 18–19
- including MVA, 104–106
- of Lewis<sup>x</sup>-KLH, 20
- of modified cytokine-secreting whole-cell vaccines, 158–159
- of Ontak, 191–192
- of polyepitope vaccines, 75–77
- of poxvirus vaccines, 97, 98–99t
- T cell reconstitution in, 220–223
- therapeutic HPV vaccine, 88–90t
- in yeast-based immunotherapy, 144, 145
- Clinics, for vaccine production support, 292
- Cloning, 121
- Clustered vaccines, 20–22
- Codon optimization, enhancing DC antigen expression via, 84
- Coinhibitory molecules, 261–262
  - APCs and, 244
- Coley, William, 243
- College of American Pathologists (CAP), 301
- Colony-forming units (CFUs), 121
- Colorectal cancers, immune-response induction in treating, 101
- Colorectal tumor hepatic metastasis model, in CD137 studies, 259
- Combination therapies
  - cancer vaccines in, xv, xvi
  - including poxvirus vectors, 102–104
  - using BCG and drugs, 35
- Complement receptor 3 (CR3), in yeast-based immunotherapy, 133
- Computed tomography (CT), in vivo imaging via, 283, 284
- Concanavalin A (ConA), PD-1 gene and, 245
- Conflict-of-interest policies, 181
- Constitutive promoters, in yeast-based vaccine vector design, 141–142
- Copenhagen rat model, allogeneic vaccines and, 155
- Copier, John, ix, 153
- Costimulatory molecules
  - APCs and, 244
  - in cancer immunotherapy, 243–268
  - modification of whole-cell vaccines with, 156–157
- Coukos, George, ix, 189
- CPG 7909 synthetic TLR9 agonist, 52–53
- CpG (cytosine–phosphate–guanine) dinucleotides, TLR9 in detecting, 44
- CpG DNA, in adjuvants, 5–6
- CpG motifs, for activating TLR9, 45
- CpG oligonucleotides (ODNs)
  - as adjuvants, 47, 48
  - classes of, 46–47
  - efficacy in mouse tumor models, 51
  - human clinical trials with, 50–51, 51–53
  - LIGHT expression and, 235
  - regulatory T cells and, 48
  - safety of, 53–54
  - in stimulating innate and adaptive immunity, 47–49
  - synergy with other adjuvants, 50
  - TLR9 activation and, 44–46
  - <sup>51</sup>Cr (chromium) isotope
    - in cancer vaccine evaluation, 298
    - in cytotoxic assays, 282–283
- Crispen, Ray, 38–39
- “Cross-dressing,” whole-cell vaccines and, 154
- Cross-presentation, 133
  - of exogenous yeast-associated antigens into MHC I pathway, 133–135, 146
- Cross-priming, 133. *See also* Priming
  - in human breast cancer therapy, 175
  - by whole-cell vaccines, 154
  - yeast-induced, 133–134
- CRT (calreticulin), in enhancing DC antigen expression, 84, 85
- Cryopreservation
  - in cancer vaccine evaluation, 298
  - quality assurance/quality control for, 302, 304
  - in vaccine monitoring, 294–295
- CTLA4 blockade, 190, 192. *See also* Cytotoxic T lymphocyte antigen 4 (CTLA4)
- CTLA4 counterregulatory signaling pathway, in immune-based therapies, 179
- CTLA4 gene, PD-1/B7-H1/B7-DC pathway and, 245
- CTL activation, 70
- CTL epitopes, 69–70
  - peptide-based vaccines and, 70–71
- CUP1* promoter, in yeast-based vaccine vector design, 142
- Curiel, Tyler J., ix, 189
- Cutaneous T cell lymphoma/leukemia, Ontak versus, 191
- CXCL12 chemokine
  - ovarian cancer and, 194
  - pDCs and, 195
- CXCR4 expression
  - ovarian cancer and, 194
  - pDCs and, 195

- Cycloaddition, in carbohydrate synthesis, 17
- Cyclophosphamide (CY)  
 in chemotherapy-modulated immune tolerance, 171  
 clinical trials of, 219–220  
 GM-CSF-secreting vaccines and, 176–177, 178  
 poxvirus vectors in combination with, 103, 104  
 versus Tregs, 192
- Cytokine expression, poxvirus vectors and, 101–102
- Cytokine flow cytometry (CFC). *See also* Flow cytometry  
 in cancer vaccine evaluation, 298–299  
 in immune monitoring, 273, 274t, 278–279, 285, 304
- Cytokine-induced killer (CIK) T cells, in vivo imaging, 283–284
- Cytokine responses, to allogeneic vaccines, 155–156
- Cytokines  
 allogeneic vaccine modifications to secrete, 157–159  
 in antigen-specific therapy, 7  
 BCG immune response and, 37  
 in cancer vaccine evaluation, 298–299  
 in CD137 studies, 260  
 costimulatory and coinhibitory molecules and, 244  
 in ELISpot assay, 275–276  
 inside tumors, 234  
 in monoclonal antibody therapy, 174  
 PD-1/B7-H1/B7-DC pathway and, 247, 251–252  
 in T cell regeneration, 221–222, 223, 224  
 in tetramer analysis, 277
- Cytokine-secreting tumor cells, 158
- Cytokine secretion, in cancer vaccine evaluation, 299
- Cytolytic CD8 T cells, vaccine activation of, xiii
- Cytomegalovirus (CMV), 52–53
- Cytoreduction, breast tumor immunity and, 170–173
- Cytosine–phosphate–guanine (CpG) site. *See* CpG entries
- Cytotoxic chemotherapy, versus CD25, 192
- Cytotoxicity assays  
 in cancer vaccine evaluation, 298  
 in immune monitoring, 274t, 282–283
- Cytotoxic T cell responses, to whole-cell vaccines, 154
- Cytotoxic T cells, bacterial vaccine vectors and, 114. *See also* Cytotoxic T lymphocytes (CTLs)
- Cytotoxic T lymphocyte antigen 4 (CTLA4), 244. *See also* CTLA4 entries  
 antitumor immunity and, xiii  
 costimulatory molecules beyond, 243–268  
 PD-1/B7-H1/B7-DC pathway and, 248, 250  
 Tregs and, 193
- Cytotoxic T lymphocytes (CTLs)  
 Ad-LIGHT administration and, 236  
 allogeneic vaccines and, 155–156  
 in CD137 studies, 258, 259  
 costimulatory-molecular whole-cell vaccine modification and, 157  
 generation in LIGHT-mediated tumor environment, 235–236  
 HER2/*neu*-specific, 176  
 immunosuppressive pathways and, 173  
 immunotherapy and, 10, 237  
 in monoclonal antibody therapy, 173  
 PD-1/B7-H1/B7-DC pathway and, 251  
 polypeptide vaccines and, 69–76  
 in yeast-based immunotherapy, 143
- Cytoxan (CY), 8
- Daclizumab  
 in immune-based therapies, 179–180  
 versus CD25, 191
- Dalgleish, Angus, ix, 153
- Daniel, Benjamin J., ix, 189
- Danishesky, Samuel J., ix, 15
- DC-based vaccines. *See also* Dendritic cells (DCs)  
 characteristics of, 82t  
 clinical trials of, 90t
- Degradation protection, with CpG ODNs, 50
- Delayed-type hypersensitivity (DTH) reactions, 4–5  
 to allogeneic vaccines, 155–156  
 in vaccine evaluation, 292, 294, 296
- Dendritic-cell-based vaccines  
 support for, 293  
 TLR signaling and, 193
- Dendritic cell lymphocytes, cancer immunotherapy strategies and, 231–232
- Dendritic cells (DCs). *See also* DC-based vaccines; Myeloid dendritic cells (mDCs); Plasmacytoid dendritic cells (pDCs)  
 activation and maturation of, 133, 134, 172  
 B7-DC ligand and, 246  
 CD137L and, 254  
 in CD137 studies, 258  
 in chemotherapy-modulated immune tolerance, 172  
 in ELISpot assay, 275  
 LIGHT expression and, 235

- Listeria monocytogenes* and, 114, 115  
 in monoclonal antibody therapy, 174  
 PD-1/B7-H1/B7-DC pathway and, 249  
 strategies for enhancing antigen expression,  
 processing, and presentation in, 84–86  
 strategies for enhancing T-cell interaction  
 with, 86, 87  
 strategies for increasing, 82–83  
 in treating HPV, 80–81  
 Treg interactions with, 194–196  
 vascular leukocytes as, 196  
 whole-cell vaccines and, 154, 160  
 in yeast-based immunotherapy, 133–134, 135  
 yeast-cell phagocytosis by, 132
- Dinileukin difitox (Ontak), 197, 198  
 in immune-based therapies, 9, 179–180,  
 191–192
- Depot effect, with CpG ODNs, 50
- Diabetes, PD-1/B7-H1/B7-DC pathway and, 246,  
 248–249
- Dicetaxel, 160
- Dihydropyrones, selective formation of, 17
- Diphtheria toxin conjugate, versus CD25, 191
- Direct assays, in cancer vaccine evaluation, 297
- Direct cloning, 121
- Disease progression, after BCG treatment, 34–35
- DNA-based vaccines  
 in antigen-specific therapy, 6  
 characteristics of, 82t  
 clinical trials of, 89–90t  
 in enhancing DC–T cell interaction, 86  
 enhancing potency of, 82–87  
 human clinical trials of, 86–87  
*Listeria monocytogenes* in, 119  
 safety of, 91  
 in treating HPV, 80, 81
- DNA encoding apoptotic proteins, in enhancing  
 DC–T cell interaction, 86
- DNA-encoding tumor antigens, dendritic cells  
 and, 81
- DNA replication, yeast-based vaccine vector  
 design and, 140
- DNA vectors  
 in antigen-specific therapy, 6, 7  
 in polyepitope technology, 72
- Docetaxel, poxvirus vectors in combination with,  
 104
- Donor lymphocyte infusions (DLIs), 218
- Donors, in carbohydrate synthesis, 17, 18
- Dose-intensive chemotherapy, in cancer  
 treatment, 218–219, 224
- Dose number, in yeast-based immunotherapy,  
 143
- Dose-response parameters, in yeast-based  
 vaccine vector design, 143–144
- Doxorubicin (DOX)  
 BCG versus, 32t, 33  
 in chemotherapy-modulated immune tolerance,  
 171, 172  
 GM-CSF-secreting vaccines and, 176, 178  
 poxvirus vectors in combination with, 103, 104
- Draining lymph nodes (DLNs), 230
- Drugs, with BCG treatment, 35
- DTH skin tests, in cancer vaccine evaluation,  
 300–301
- E6 gene, human papillomavirus and, 117, 118
- E7 gene  
 DNA-based vaccines and, 119  
 human papillomavirus and, 117, 118
- EBV-associated malignancies, polyepitope-based  
 treatment of, 73–75, 76. *See also*  
 Epstein–Barr virus (EBV)
- Effective clinical responses, 10–11
- Effector CD4<sup>+</sup> T cells. *See also* CD4<sup>+</sup> T cells  
 in increasing antigen-expressing DCs, 83  
 inside tumors, 234  
 Tregs and, 190, 193
- Effector CD8<sup>+</sup> T cells. *See also* CD8<sup>+</sup> T cells  
 in evaluating immune competence, 297  
 in increasing antigen-expressing DCs, 83  
 inside tumors, 234, 235  
 Tregs and, 190, 193
- Effector T cells. *See also* T cell entries  
 carcinogenesis and, 229  
 immunotherapy and, 8–9  
 in treating HPV, 80–81
- Ehrlich, Paul, 243, 244
- ELISpot (enzyme-linked immunospot) assay. *See*  
*also* Enzyme-linked immunosorbent assay  
 (ELISA)  
 in cancer vaccine evaluation, 298, 299–300  
 in immune monitoring, 272, 273, 274–276,  
 285  
 quality assurance/quality control for, 303, 304
- Emens, Leisha A., ix, 169
- Encoded antigens, in increasing antigen-  
 expressing DCs, 82
- Endocrine therapy, breast tumor immunity and,  
 173, 174–175
- Endoplasmic reticulum (ER)  
 in enhancing DC antigen expression, 85  
 TLR9 in, 45–46
- Endosomal acidification/maturation, TLR9 in,  
 45–46
- Endosomes, stimulating innate and adaptive  
 immunity in, 47

- Endothelial cells, PD-1/B7-H1/B7-DC pathway and, 249
- Endothelial precursor cells, vascular leukocytes as, 196
- Energix-B, CpG ODNs used with, 50, 51
- Enhancement  
with CpG ODNs, 50  
of tumor vaccines via chemotherapy, 170–171
- ENO2* (enolase) promoter, in yeast-based vaccine vector design, 142
- Enzyme-linked immunosorbent assay (ELISA), 23. *See also* ELISpot (enzyme-linked immunosorbent assay) assay  
in immune monitoring, 273, 274t
- Eosinophils, whole-cell vaccines and, 154
- Epidermal growth factor receptor (EGFR)  
in monoclonal antibody therapy, 174  
in yeast-based immunotherapy, 135, 138–139
- Epirubicin, BCG versus, 32
- Episomal gene expression, 121
- Episomal plasmids, in yeast-based vaccine vector design, 139–140
- Epitopes. *See* CTL epitopes; Polyepitope vaccines  
“Epitope spreading,” xiv
- Epstein–Barr nuclear antigens (EBNAs), in treatment of EBV-associated malignancies, 73
- Epstein–Barr virus (EBV), 52–53. *See also* EBV-associated malignancies  
polyepitope technology and, 71, 72
- Equine encephalitis virus, as cancer-therapy vaccine vector, 96
- Eroside, clinical trials of, 219
- Escherichia coli*, in constructing *Listeria monocytogenes* vaccine vectors, 119, 120, 121
- Esophageal carcinoma (EC1), CD137L and, 254
- Estrogen receptor (ER), in monoclonal antibody therapy, 174
- Estrogen receptor  $\alpha$  (ER $\alpha$ ), 169, 180
- Evaluation, of cancer vaccines, 291–307
- Exemestane, in endocrine therapy, 174
- “Exhausted T cells,” PD-1/B7-H1/B7-DC pathway and, 250
- Experimental autoimmune encephalitis (EAE), PD-1/B7-H1/B7-DC pathway and, 246, 249
- Experimental vaccine development, 3
- Expressed sequences tag (EST) database, in microarray analysis, 280
- Extracellular receptor kinase (ERK), CpG ODNs in stimulating, 47
- Extrachromosomal plasmids, in yeast-based vaccine vector design, 139–140
- Ex vivo T cell analysis, 52–53  
in immune monitoring, 272
- Flanking amino acid sequences, in CTL epitopes, 71–72
- Flow cytometry. *See also* Cytokine flow cytometry (CFC)  
in immune monitoring, 273, 274t, 278–279, 285  
in T cell proliferation assays, 282
- Fludarabine (Flu)  
clinical trials of, 219–220  
versus Tregs, 192
- Fluorescence-activated cell sorter (FACS) analysis, 19  
in CD137 studies, 258  
PD-1/B7-H1/B7-DC pathway and, 250
- Fluorescent dye, in qRT-PCR, 279
- Fms-like tyrosine kinase 3 (flt3) ligands, in increasing antigen-expressing DCs, 83
- Food and Drug Administration (FDA)  
quality assurance/quality control by, 303  
safety of yeast-based therapeutics and, 144–145  
vaccine production and, 293
- Foreign antigens, in yeast-based immunotherapy, 143
- Fowlpox virus  
boosts for, 100  
immune-response induction and, 101
- Franzusoff, Alex, ix, 131
- Frappier, Armand, 31
- Freund’s adjuvant, CpG ODN coadministered with, 49
- Fu, Yang-Xin, ix, 229
- Fucosyl-GM1 antigen, 20
- Fucosyl-GM1–KLH conjugate, 20, 21. *See also* Keyhole limpet hemocyanin (KLH)
- Fully synthetic antitumor vaccines,  
carbohydrate-based, 15–27
- Fulvestrant, in endocrine therapy, 174
- Functional assays, in cancer vaccine evaluation, 297
- FVB transgenic mice, *Listeria monocytogenes* in, 118
- GAPDH* (glyceraldehyde-3-phosphate dehydrogenase) promoter, in yeast-based vaccine vector design, 142
- Gastrointestinal (GI) tract cancers,  
immune-response induction in treating, 101
- GD3 antigen, in polyvalent vaccines, 22

- GD3 ganglioside, CpG ODN coadministered with, 49
- Gene expression  
episomal, 121  
in *Listeria monocytogenes*, 119, 120
- Gene expression cassettes, in yeast-based vaccine vector design, 139–140
- Gene gun delivery, of DNA, 82
- Genes, in microarray analysis, 280–281
- Gene therapy approach, in CD137 studies, 257
- Genetic changes, associated with carcinogenesis, 229–230
- Genetic engineering, of *Listeria monocytogenes*, 114
- Genetic manipulation, in constructing *Listeria* vaccine vectors, 121
- Genitourinary cancer immunotherapy, bacillus Calmette–Guérin in, 29–42
- GI-3000 yeast strains, in yeast-based immunotherapy, 138
- GI-4000-01 phase I safety and immunogenicity, 145
- GI-4000-02 phase II testing, 145
- GI-4000 yeast strains  
safety of yeast-based therapeutics and, 144–145  
in yeast-based immunotherapy, 135–137, 138, 139
- GL261 glioma cells, in CD137 studies, 261
- Glioma cell lines, PD-1/B7-H1/B7-DC pathway and, 251–252
- Globo-H-KLH conjugate. *See also* Keyhole limpet hemocyanin (KLH)  
clinical trials of, 18–19  
in pentavalent vaccine, 24, 25  
synthesis of, 18  
in trivalent vaccine, 23  
as vaccine, 18
- $\beta$ -Glucan receptor, in yeast-based immunotherapy, 133
- Glucocorticoid-induced tumor necrosis factor receptor (GITR), in immune-based therapies, 180. *See also* Anti-GITR antibodies
- Glycals, in carbohydrate synthesis, 17, 18
- Glycoconjugates, as adjuvants, 5
- Glycoprotein molecules, APCs and, 244
- Glycoproteins  
with cell-surface carbohydrates, 15, 16  
clustered vaccines and, 21
- Glycosphingolipids, cell-surface, 15
- GM2 antigen  
in hexavalent vaccine, 24  
in pentavalent vaccine, 25
- GM-CSF-secreting vaccines. *See also* Granulocyte–macrophage colony stimulating factor (GM-CSF)  
chemotherapy and, 176–177  
human clinical trials of, 178  
monoclonal antibody therapy and, 177–178  
*neu* transgenic mouse model and, 175–176
- Golgi zone, in cancer vaccine evaluation, 299
- Good laboratory practice (GLP)  
in cancer vaccine use, 10  
in vaccine monitoring, 293t, 302t, 304
- gp100 melanoma antigen, 96  
in tetramer analysis, 277
- Granulocyte–macrophage colony stimulating factor (GM-CSF). *See also* GM-CSF-secreting vaccines  
in antigen-specific therapy, 7  
BCG immune response and, 37  
in combination therapies, 103  
cytokine-secreting tumor cells and, 158–159, 159–160  
in ELISpot assay, 276  
in enhancing DC–T cell interaction, 86  
immunotherapy and, 8  
in mouse tumor models, 51  
poxvirus vectors and, 101–102  
in yeast-based immunotherapy, 134
- Green fluorescent protein (GFP) gene, in in vivo imaging, 283
- Gress, Ronald, x, 217
- Guérin, Camille, 30
- Guinea pigs, intracellular bacteria-based vaccines in, 122
- Guo, Zhimin, x, 131
- Heaf gun, 32
- Heatshock proteins, following syngeneic HSCT, 210
- Helper CD4 T cells. *See also* CD4<sup>+</sup> T cells  
GM-CSF-secreting vaccines and, 176, 177  
vaccine activation of, xiii
- Helper T cells, BCG immune response and, 37. *See also* T cell entries
- Hematopoietic stem cell transplantation (HSCT)  
cancer immunity suppression and, 211, 212, 213  
following high-dose therapy, 205–206  
future of, 214  
high-dose chemotherapy and, 219–220  
immunotherapy and, 9  
T cell reconstitution following, 220–223  
tumor burden and, 212–213  
tumor mass and, 218–219

- Hematopoietic stem cell transplantation (HSCT),  
(Continued)  
vaccines and, 217–228  
window of survival following, 219
- Hematuria, during BCG treatment, 38
- Hepatic metastasis model, in CD137 studies, 259
- Hepatitis B, application of polyepitope technology to, 74t
- Hepatitis B surface antigen (HBsAg), CpG ODN coadministered with, 49, 51
- Hepatitis C, application of polyepitope technology to, 74t
- HER2 epitopes, clinical studies of, 77
- HER2/*neu*-negative breast cancers, 178
- HER2/*neu*-positive breast cancers, 178
- HER2/*neu*-positive tumors, 176
- HER2/*neu* protooncogene, 175. *See also neu* transgenic mouse model
- HER2/*neu*-specific CTLs, 176, 177–178
- HER2/*neu*-specific monoclonal antibody, 169–170, 173, 174
- HER2/*neu*-specific T cells, 176  
in immune-based therapies, 179
- HER2/*neu* tyrosine kinase expression, breast cancer and, 118, 124, 169
- Herpes simplex virus type 1 (HSV-1), in increasing antigen-expressing DCs, 82
- Herpesvirus entry mediator (HVEM), in creating tumor lymphoid tissue, 232–233, 235
- Heterologous proteins, in yeast-based vaccine vector design, 141–142
- Hexamer CpG motif, in activating TLR9, 45
- Hexavalent vaccines, evaluation of, 24, 25
- High-dose therapy. *See also* Chemotherapy alternatives to, 219–220  
followed by autologous hematopoietic stem cell transplantation, 205–206
- High-dose vitamin administration, with BCG treatment, 35
- HLA-A2 epitopes, clinical studies of, 76, 77. *See also* Human leukocyte antigen (HLA) types
- HLA genotypes, in yeast-based immunotherapy, 146
- HLA-restricted peptide epitopes, in immune monitoring, 271
- HLA transgenic mice, LMP polyepitopes and, 74
- Hodge, James W., x, 3
- Hodgkin's lymphoma (HL)  
polyepitope technology and, 72, 74t  
treatment of EBV-associated malignancies and, 73, 75
- Homeostatic cytokines, in T cell regeneration, 223
- Homogeneous carbohydrates, synthesis of, 16–17
- HPV-associated cervical cancer, as antigen-specific cancer immunotherapy model system, 79–94. *See also* Human papillomavirus (HPV)
- HPV vaccines  
characteristics of, 82t  
clinical trials of, 88–90t
- H-Ras protein, in yeast-based immunotherapy, 135–137
- Human cancer cells, costimulatory-molecular whole-cell vaccine modification and, 157
- Human clinical trials. *See also* Clinical trials with CpG ODNs, 50–51, 51–53  
in DNA vaccine development, 86–87  
of GM-CSF-secreting vaccines with standard breast cancer therapy, 178
- Human cytomegalovirus (HCMV), polyepitope technology and, 72
- Human diseases  
peptide-based vaccines for treating, 70–71  
polyepitope technology applications to, 74t, 76
- Human glioma cell lines, PD-1/B7-H1/B7-DC pathway and, 251–252
- Human immunodeficiency virus (HIV)  
application of polyepitope technology to, 74t, 76  
PD-1/B7-H1/B7-DC pathway and, 250  
polyepitope technology and, 72
- Human leukocyte antigen (HLA) types. *See also* HLA entries  
in immune monitoring, 271  
LMP polyepitopes and, 74, 75  
peptide-based vaccines and, 70–71  
in tetramer analysis, 277  
in vaccine monitoring, 294
- Human papillomavirus (HPV). *See also* HPV entries  
application of polyepitope technology to, 74t, 77  
in CD137 studies, 258  
in immune monitoring, 272  
*Listeria monocytogenes* versus, 117–118  
types of, 80
- Human papillomavirus–based vaccine, xv–xvi
- Humans  
*Listeria monocytogenes* cancer immunotherapy in, 116, 117–122, 122–123, 123–124  
safety of CpG ODN in, 53
- Human specimens, vaccine production and, 293–294. *See also* Specimen collection
- Human T cell leukemia, CD137 and, 253
- Hung, Chien-Fu, x, 79
- Hypothesis-driven preclinical studies, of cancer vaccines, xiii

- ICOS gene, PD-1/B7-H1/B7-DC pathway and, 245
- IgG antibodies, clustered vaccines and, 21–22
- IgM antibodies, clustered vaccines and, 21–22.  
*See also* Immunoglobulin M (IgM)
- Immature myeloid cells, 197  
tumors and, 234–235
- Immune assays, in cancer vaccine use, 10
- Immune-based therapies, novel, 178–180
- Immune cell phenotype changes, in vaccine monitoring, 294
- Immune cells, in evaluating immune competence, 297
- Immune competence, evaluation of, 296–297
- Immune costimulatory molecules, immunotherapy and, 10
- Immune-depleting chemotherapy, in cancer treatment, 217–218
- Immune evaluation, of cancer vaccines, 291–307
- Immune monitoring  
assay validation in, 284  
of cancer vaccines and immunotherapy, 271–289  
current tumor immunotherapy approaches to, 272–284  
need for, 271–272  
in vaccine evaluation, 292
- Immune monitoring assays, 273–274, 284–285
- Immune reconstitution, following autologous HSCT, 206–210
- Immune response  
to BCG, 37  
cancer therapy and, 205–206  
as cancer vaccine objective, 295  
CD137 and, 255–256, 257–258  
in immune monitoring, 273  
intratumor generation of antitumor, 229–242  
monitoring of, 303–304  
PD-1/B7-H1/B7-DC pathway and, 253  
Th1-like, 43, 44  
toll-like receptors and, 43–44  
to tumor-associated antigens, 189–190  
tumor cells and, 171  
in yeast-based immunotherapy, 143–144, 146
- Immune screen, 296
- Immune status, in evaluating immune competence, 297
- Immune stimulatory CpG ODNs, classes of, 46–47
- Immune suppression, tumor-induced, 218, 219
- Immune surveillance, in vaccine evaluation, 291
- Immune system  
adjuvant stimulation of, 4–6  
cancer and, 4  
in cancer treatment, 217  
theories of, 243–244  
tumors and, 3  
vaccine activation of, xiii, xv  
versus tumor cells, 15–16
- Immune tolerance, chemotherapy-modulated, 171–172
- Immunity. *See* Adaptive immunity; Innate immunity
- Immunization, as cancer immunotherapy strategy, 230–231
- Immunization routes, for intracellular bacteria-based vaccines, 122
- Immunodeficiencies, cancer and, 4
- Immunogenic carrier molecules, 16
- Immunogenicity, allogeneic vaccines and, 155
- Immunoglobulin G (IgG), clustered vaccines and, 21–22
- Immunoglobulin M (IgM). *See also* B-cell-mediated IgM response  
clustered vaccines and, 21–22  
fucosyl-GM1–KLH conjugate and, 20
- Immunoglobulins (Igs)  
in cancer vaccine evaluation, 301  
in CD137 studies, 254–255, 258  
in evaluating immune competence, 296
- Immunologic checkpoints, manipulation of, 178–180
- Immunologic memory, in vaccine evaluation, 292
- Immunoprophylaxis, history of, 243–244
- Immunoreceptor tyrosine-based inhibiting motif (ITIM), PD-1/B7-H1/B7-DC pathway and, 245, 246
- Immunoreceptor tyrosine-based switch motif (ITSM), PD-1/B7-H1/B7-DC pathway and, 245, 246
- Immunostimulatory complexes (ISCOMs)  
CTL activation and, 70  
polyepitope technology and, 72
- Immunosuppression, in BCG treatment, 34
- Immunosuppressive entities, xiii, xvi
- Immunosuppressive pathways, 173
- Immunotherapy, 224. *See also* Antigen-specific cancer immunotherapy; Cancer immunotherapy; Yeast-based immunotherapy  
advances in immune monitoring strategies for, 271–289  
bacillus Calmette–Guérin, 29–42  
cancer vaccines and, 4  
in immune monitoring, 273  
improving BCG, 35  
tumor cells in, 7–10

- Immunotherapy trials, immune monitoring of, 272
- Indirect assays, in cancer vaccine evaluation, 297
- Inducible promoters, in yeast-based vaccine vector design, 141–142
- Infectious agents, polypeptide technology and, 72
- Infectious disease vaccines, CpG ODNs as adjuvants for, 49
- Innate immunity
  - bacterial vaccine vectors and, 114
  - coupling yeast-based cancer immunotherapy with, 131–149
  - CpG ODNs in stimulating, 47–49
- Interassay variability, in cancer vaccine evaluation, 298
- Intercellular adhesion molecule I (ICAM-I)
  - BCG immune response and, 37
  - in combination therapies, 102, 103
  - immune-response induction and, 101
- Interferon (IFN)
  - in BCG combination immunotherapy, 35
  - CpG ODNs in stimulating, 47
- Interferon alpha (IFN $\alpha$ )
  - CpG ODN classes and, 46
  - in pDC contamination, 45
- Interferon gamma (IFN $\gamma$ )
  - BCG immune response and, 37
  - in CD137 studies, 258, 260
  - in ELISpot assay, 274–275
  - in flow cytometry, 278
  - following syngeneic HSCT, 209
  - LIGHT expression and, 235
  - Listeria monocytogenes* and, 115
  - PD-1/B7-H1/B7-DC pathway and, 247–248, 249, 250, 251, 252
  - in T cell activation, 53
  - in yeast-based immunotherapy, 146
- Interleukin 1 (IL-1), BCG immune response and, 37
- Interleukin 1 receptor-associated kinase (IRAK-1), CpG ODNs in stimulating, 47
- Interleukin 2 (IL-2), xiv, 96
  - in BCG combination immunotherapy, 35
  - BCG immune response and, 37
  - CD4<sup>+</sup>CD25<sup>+</sup> Tregs and, 191–192
  - CD25 and, 190
  - CD137L and, 255
  - in combination therapies, 103
  - cytokine-secreting tumor cells and, 158
  - in immune-based therapies, 179–180
  - PD-1/B7-H1/B7-DC pathway and, 249, 251, 252
  - poxvirus vectors and, 101
- Interleukin 6 (IL-6), BCG immune response and, 37
- Interleukin 7 (IL-7), in T cell regeneration, 221–222, 223
- Interleukin 8 (IL-8), BCG immune response and, 37
- Interleukin 10 (IL-10)
  - BCG immune response and, 37
  - inside tumors, 234
  - mDCs and, 195–196
  - PD-1/B7-H1/B7-DC pathway and, 247, 252
  - vascular leukocytes and, 196
- Interleukin 12 (IL-12)
  - BCG immune response and, 37
  - in CD137 studies, 259
  - Listeria monocytogenes* and, 115
  - in stimulating innate and adaptive immunity, 47
- Interleukin 15 (IL-15), in T cell regeneration, 223
- Interleukins (ILs)
  - cytokine-secreting tumor cells and, 158, 159
  - in ELISpot assay, 276
  - in flow cytometry, 278
- Intracellular bacteria, as vaccine vectors, 114
- Intracellular cytokine flow cytometry (CFC), in immune monitoring, 273, 274t, 278–279
- Intradermal (ID) administration, of bacillus Calmette–Guérin, 31–32
- Intravesical administration, of bacillus Calmette–Guérin, 31–32
- Investigational new drug (IND) applications, safety of yeast-based therapeutics and, 144
- Investigator-initiated drug (IND) application, 293
- In vitro assays, in immune monitoring, 273
- In vitro sensitization (IVS), in cancer vaccine evaluation, 301
- In vitro stimulation (IVS), in ELISpot assay, 275
- In vivo assays, in immune monitoring, 273
- In vivo imaging, advances in, 283–284
- Jenner, Edward, 243
- Jing, Weiqing, x, 205
- Johns Hopkins University, 181
- Johnson, Bryon D., x, 3, 205
- Jurkat cell line, CD137 mRNA in, 253
- Kaufman, Howard L., x, 271
- Kelley, Victoria, x, 131
- Keratinocyte growth factor (KGF), 223
- Keyhole limpet hemocyanin (KLH), 5. *See also*
  - Fucosyl-GM1–KLH conjugate;
  - Globo-H-KLH conjugate; KLH carrier

- protein; Lewis<sup>y</sup>-KLH; TF(c)-KLH clusters;  
Tn(c)-KLH clusters  
in BCG combination immunotherapy, 35
- Khanna, Rajiv, x, 69
- Kim-Schulze, Seunghee, x, 271
- King, Thomas H., x, 131
- KLH carrier protein. *See also* Keyhole limpet  
hemocyanin (KLH)  
in pentavalent vaccine, 24, 25  
in polyvalent vaccines, 22  
in trivalent vaccine, 23
- K-Ras protein, in yeast-based immunotherapy,  
135–137
- Krieg, Arthur M., x, 43
- Kryczek, Ilona, x, 189
- Kupffer cells, PD-1/B7-H1/B7-DC pathway and,  
249
- Laboratories, for vaccine production support, 292
- Laboratory assays, in cancer vaccine use, 10
- Lamm, Donald L., x, 29
- Latent membrane protein (LMP)  
antigens/polyepitopes, treatment of  
EBV-associated malignancies and, 73–75
- Late-stage cancer, treatment of, 79
- LCMV (lymphocytic choriomeningitis virus)  
infection, PD-1/B7-H1/B7-DC pathway and,  
250
- Lethal total body irradiation, conditioning with,  
206, 207, 208, 209
- Letrozole, in endocrine therapy, 174
- leu2d* mutation, yeast-based vaccine vector  
design and, 140–141
- Leukemia, fludarabine versus, 192
- Leukocyte function-associated antigen 3 (LFA-3)  
in combination therapies, 103  
immune-response induction and, 101
- Lewis<sup>y</sup>-KLH. *See also* Keyhole limpet  
hemocyanin (KLH)  
clinical trials of, 20  
in pentavalent vaccine, 24–25  
in polyvalent vaccines, 22  
in trivalent vaccine, 23
- Lewis<sup>y</sup> pentasaccharide, 20
- LIGHT expression  
in cell interactions, 235  
in creating tumor lymphoid tissue, 232–234  
immunotherapy and, 10  
treatment of metastases and, 235–236
- LIGHT-mediated tumor environment, CTL  
generation in, 235–236
- Lipopolysaccharide (LPS), in yeast-based  
immunotherapy, 134
- Lipopolysaccharide-like structures, as adjuvants,  
5
- Listeria monocytogenes* (LM)  
in antigen-specific therapy, 7, 113–129  
as breast cancer vaccine, 118  
as cervical cancer vaccine, 117–118  
constructing vectors from, 119–122  
as DNA carrier vaccine, 119  
infection with, 115  
safety concerns related to, 122–123  
as vaccine vector, 114–117
- Listeriosis, 123
- Live recombinant vaccine vectors, 114–122
- Live vectors, safety concerns related to, 122–123
- Live vector vaccines  
with antigen-presenting cells, 81  
characteristics of, 82t  
clinical trials of, 88t
- LLO (listeriolysin O) hemolytic protein  
*Listeria monocytogenes* and, 116, 117, 118  
safety concerns related to, 123
- LLO-E7 fusion gene, in *Listeria monocytogenes*,  
119, 120
- LM-ActA-E7 vaccine, human papillomavirus  
and, 117–118
- LM-LLO-E7 vaccine, human papillomavirus and,  
117–118, 123–124
- LncaP allogeneic cell line, 156
- Lobund–Wistar model of prostate cancer,  
allogeneic vaccines and, 155
- “Low copy” plasmids, yeast-based vaccine  
vector design and, 140
- LTβR receptor, in creating tumor lymphoid  
tissue, 232, 233
- Lu, Yingnian, x, 131
- Luciferase (Luc) gene, in in vivo imaging, 283
- Lung tumor model, in yeast-based  
immunotherapy, 135–136
- Lupus erythematosus, PD-1/B7-H1/B7-DC  
pathway and, 246
- LyD9 cells, PD-1 gene and, 245
- Lymph nodes, PD-1/B7-H1/B7-DC pathway and,  
252
- Lymph node sensitization, in CD137 studies, 261
- Lymphoblastoid cell lines (LCLs), treatment of  
EBV-associated malignancies and, 73, 75
- Lymphocyte-associated globulin 3 (LAG-3), in  
immune-based therapies, 180
- Lymphocyte homeostasis, in evaluating immune  
competence, 297
- Lymphocytes. *See also* T lymphocytes  
cancer and, 4  
carcinogenesis and, 229
- Lymphocytic leukemia, fludarabine versus, 192

- Lymphoid tissue reconstitution, following syngeneic HSCT, 207, 209
- Lymphoma cells, in CD137 studies, 259
- Lymphopenia  
breast tumor vaccines and, 170, 171  
following HSCT, 206–210
- Lymphotoxin  $\alpha$  (LT $\alpha$ )  
in creating tumor lymphoid tissue, 232  
PD-1/B7-H1/B7-DC pathway and, 250
- Lymphotoxin  $\alpha 1\beta 2$  (LT $\alpha 1\beta 2$ ), in creating tumor lymphoid tissue, 232
- Lymphotoxin  $\beta$  (LT $\beta$ ), in creating tumor lymphoid tissue, 232
- Lysosome-associated membrane protein 1 (LAMP-1), in enhancing DC antigen expression, 84, 85
- Macrophages (M $\phi$ )  
antitumor immunity and, xiii  
*Listeria monocytogenes* and, 114, 115  
whole-cell vaccines and, 154  
yeast-cell phagocytosis by, 132
- Magnetic resonance imaging (MRI), in vivo imaging via, 283, 284
- Maintenance immunotherapy, after BCG treatment, 34–35
- Major histocompatibility complex (MHC), xv.  
*See also* MHC entries; Peptide–MHC complex  
in antigen-specific therapy, 7  
clinical studies of, 76  
costimulatory-molecular whole-cell vaccine modification and, 157  
cytotoxic T lymphocytes and, 69, 70  
immune-response induction and, 100  
peptide-based vaccines and, 70–71  
whole-cell vaccines and, 154
- Malaria  
application of polyepitope technology to, 74t, 76  
polyepitope technology and, 72
- Mannose receptor, in yeast-based immunotherapy, 133
- Marek's disease virus type 1 (MDV-1), in increasing antigen-expressing DCs, 82
- MART1 melanoma antigen, 96  
in tetramer analysis, 277  
yeast-expressed, 138t, 139
- MCA26 tumor cells, in CD137 studies, 259
- MCA205 sarcoma cells, in CD137 studies, 261
- McCullough, David, 31
- MCF-7 cell lines, globo-H antigen and, 18
- Mediastinal B cell lymphoma,  
PD-1/B7-H1/B7-DC pathway and, 251
- Melan-A human tumor antigen, T cell vaccination with, 52
- Melanoma  
allogeneic whole-cell vaccines versus, 153, 155, 156, 160  
application of polyepitope technology to, 74t, 76, 77  
in CD137 studies, 261  
cytokines versus, 157–158
- Melanoma antigens, 96  
in yeast-based immunotherapy, 135
- Melphalan, clinical trials of, 219
- Memorial Sloan Kettering (MSK), bacillus Calmette–Guérin trials at, 31
- Mesothelin, in yeast-based immunotherapy, 135
- Metastases, CTL and LIGHT in treating, 235–236
- Metastatic cancer, GI-4000–01 phase I safety and immunogenicity in, 145
- Metastatic tumors, treatment of, 217
- Metronomic chemotherapy, 173
- MHC class I pathway. *See also* Major histocompatibility complex (MHC)  
bacterial vaccine vectors and, 114  
in CD137 studies, 257  
in combination therapies, 102, 103–104  
cross-presentation of exogenous yeast-associated antigens into, 133–135  
enhancing DC antigen expression via, 84, 85  
*Listeria monocytogenes* and, 115  
in monoclonal antibody therapy, 173  
PD-1/B7-H1/B7-DC pathway and, 248, 250  
whole-cell vaccines and, 154  
yeast-based immunotherapy and, 132, 133, 146
- MHC class II-invariant chain (Ii), in enhancing DC antigen presentation, 85
- MHC class II pathway  
bacterial vaccine vectors and, 114  
CD137L and, 257  
in enhancing DC antigen expression, 84, 85–86  
*Listeria monocytogenes* and, 115  
whole-cell vaccines and, 154  
yeast-based immunotherapy and, 132, 133, 146
- MHC class II<sup>+</sup> antigen-presenting cells, in creating tumor lymphoid tissue, 232
- Mice. *See also* Mouse tumor models; *neu* transgenic mouse model  
Ad-LIGHT administration to, 236  
autologous HSCT models in, 206, 207, 208, 209, 210  
CD137-deficient, 254–255, 256  
CD137L studies in, 257–258

- CD137 mRNA expression in, 254. *See also* mRNA
- CD137 protein in, 253
- intracellular bacteria-based vaccine boosts in, 121
- in vivo imaging in, 283
- Listeria monocytogenes* cancer immunotherapy in, 116–117, 118
- PD-1/B7-H1/B7-DC pathway studies in, 248–249, 251, 252–253
- PD-1-deficient, 246
- safety of CpG ODN in, 53–54
- TLR9 in, 44–45
- Microarray analysis, in immune monitoring, 274t, 280–281
- Microtiter plate, in ELISpot assay, 275
- Minimal residual disease (MRD)
- in evaluating immune competence, 297
- in vaccine evaluation, 292
- Mitomycin C, BCG versus, 32–33, 34–35
- MMTV mammary-specific promoter, 175
- Model systems, HPV-associated cervical cancer as, 79–94. *See also* Mouse tumor models; *neu* transgenic mouse model
- Modified vaccinia Ankara (MVA) vaccines, 104
- clinical trials of, 88t, 99t, 104–106
- Monitoring, of vaccine administration, 294, 296
- Monitoring strategies, for cancer vaccines and immunotherapy, 271–289
- Monoclonal antibodies
- in flow cytometry, 278
- versus CD25, 190–191
- Monoclonal antibody therapy, GM-CSF-secreting vaccines and, 177–178
- Monoclonal T cells, in tetramer analysis, 276, 277
- Monovalent vaccines, unimolecular, 18–20
- Montanide
- in cancer vaccines, 296
- CpG ODNs used with, 50
- Mortality, after BCG treatment 34–35
- Mouse tumor models, 135–137. *See also* Mice; *neu* transgenic mouse model
- CpG ODNs in, 51
- mRNA, in microarray analysis, 280, 281. *See also* CD137 mRNA
- MUC1 antigen
- CpG ODN coadministered with, 49
- HCST and, 218
- in combination therapies, 102
- in polyvalent vaccines, 22
- poxvirus vectors and, 101
- yeast-expressed, 138–139
- MUC2 antigen, in polyvalent vaccines, 22
- Mucin polypeptide core molecules, in polyvalent vaccines, 22
- Mucins, clustered vaccines and, 21
- Multiantigen products, in yeast-based vaccine vector design, 142
- Multimer binding, 304
- Multiparameter flow cytometry standardization, 278
- Multiplex arrays, in cancer vaccine evaluation, 304
- Multiplex assays, in cancer vaccine evaluation, 297–298, 304
- Multivalent vaccines, unimolecular, 23–25
- Munson, Sibyl, x, 131
- Mutated Ras proteins, in yeast-based immunotherapy, 135–137
- Mutations, in yeast-based vaccine vector design, 139–141
- Mycobacteria
- as adjuvants, 4–5
- as bacterial vaccine vectors, 114
- in tuberculosis, 30
- Mycobacterium tuberculosis* hsp (heatshock protein), 70
- in clinical trials of DNA-based vaccines, 87
- in enhancing DC antigen expression, 84
- MyD88 adaptor molecule, CpG ODNs in stimulating, 47
- Myeloablative chemotherapy, breast tumor vaccines and, 171
- Myelodysplastic syndrome (MDS), CD137L and, 254
- Myeloid cells
- immature, 197
- tumors and, 234–235
- Myeloid dendritic cells (mDCs)
- PD-1/B7-H1/B7-DC pathway and, 252
- in T cell activation, 53
- Treg interactions with, 194, 195–196
- Myeloid progenitors, CD137L and, 254
- Nasopharyngeal carcinoma (NPC)
- application of polyepitope technology to, 74t
- polyepitope technology and, 72
- treatment of EBV-associated malignancies and, 73, 75
- Natural killer (NK) cells
- in CD137 studies, 257, 258, 259
- CpG ODNs in stimulating, 47, 53
- following syngeneic HSCT, 210
- LIGHT expression and, 235

- Natural killer (NK) cells (*Continued*)  
*Listeria monocytogenes* and, 115  
 in stimulating innate and adaptive immunity, 47  
 TLR9 expression in, 45  
 vaccine activation of, xiii  
 whole-cell vaccines and, 154
- Neoantigens  
 associated with carcinogenesis, 229  
 in yeast-based immunotherapy, 135
- Nephrectomy, BCG versus, 36
- Neuroblastoma, 208, 209, 210
- neu* transgenic mouse model. *See also* HER2/*neu* entries  
 breast tumor immunity and, 175–178  
 combining GM-CSF-secreting vaccination and chemotherapy in, 176–177  
 GM-CSF-secreting vaccination and monoclonal antibody therapy in, 177–178  
 GM-CSF-secreting vaccines and, 175–176  
 human clinical trials and, 178
- Neutrophils  
*Listeria monocytogenes* and, 114, 115  
 yeast-cell phagocytosis by, 132
- Newcastle disease virus (NDV), as cancer-therapy vaccine vectors, 96
- NOD mice, PD-1/B7-H1/B7-DC pathway studies in, 248–249
- Non-Hodgkin's lymphoma (NHL), CD137L and, 254
- Nonmyeloablative chemotherapy, immunotherapy and, 9
- Nonspecific assays, in cancer vaccine evaluation, 297
- North America, BCG treatment in, 38
- N-Ras protein, in yeast-based immunotherapy, 135–137
- Nucleic acid vaccines. *See also* DNA-based vaccines  
 with antigen-presenting cells, 81  
 characteristics of, 82t
- ODN backbone, in activating TLR9, 45
- ODN uptake, 45
- Oligodeoxynucleotide motifs, in BCG, 37
- Oligodeoxynucleotides (ODNs)  
 in adjuvants, 5–6  
 CpG-specific responses to, 44
- Oligosaccharides  
 synthesis of, 17  
 tumor-associated, 16
- Oncogenes, 4
- Oncology, historical background of, 4
- Ontak, 197, 198  
 in immune-based therapies, 9, 179–180, 191–192
- OnyCap23 allogeneic cell line, 156
- Open reading frames (ORFs), 119
- Orentas, Rimas J., x, 3
- Origin of replication, yeast-based vaccine vector design and, 140
- Ornstein, Moshe, x, 271
- Ovalbumin, in yeast-based immunotherapy, 133–134, 135
- Ovarian ablation, in endocrine therapy, 174–175
- Ovarian cancer  
 CXCL12 chemokine and, 194  
 Lewis<sup>x</sup>-KLH and, 20  
 vascular leukocytes and, 196
- OVCAR-3 cells, Lewis<sup>x</sup>-KLH and, 20
- OX40 pathway, in immune-based therapies, 179
- P4E6 allogeneic cell line, 156
- p60-dal* in *trans* complementation system, 120
- P815 cells  
 in CD137 studies, 258, 260  
 PD-1/B7-H1/B7-DC pathway and, 251
- Paclitaxel (PTX), 8  
 breast tumor vaccines and, 171  
 in chemotherapy-modulated immune tolerance, 171–172  
 clinical trials of, 219  
 GM-CSF-secreting vaccines and, 176, 177  
 in monoclonal antibody therapy, 174  
 poxvirus vectors in combination with, 103, 104
- PADRE (pan HLA-DR binding epitope), in enhancing DC antigen presentation, 85–86
- pAM401 shuttle plasmid, 120–121
- Pancreatic cancer, GI-4000-02 phase II testing in, 145
- Pancreatic cell lines, cytokine-secreting, 159
- Pancreatic islet  $\beta$  cells, PD-1/B7-H1/B7-DC pathway and, 248
- Paracrine secretion, of GM-CSF, 175
- Paramyxoviruses, as cancer-therapy vaccine vectors, 96
- Parker, Joanne, x, 131
- Particle-associated molecular patterns (PAMPs), in yeast-based immunotherapy, 132
- Passenger antigens, with vaccine vectors, 114
- Paterson, Yvonne, x, 113
- PC61 monoclonal antibody, versus CD25, 190–191
- PD-1 (programmed death 1) gene. *See also* Apoptosis  
 discovery and functions of, 245  
 expression of, 246

- PD-1/B7-H1/B7-DC pathway and, 245–247
  - structure of, 245
- PD-1/B7-H1/B7-DC pathway, 245–253
  - costimulatory and coinhibitory molecules and, 244, 247
- PD-1-deficient mice, 246
- PD-E7/D16E7 vaccines, clinical trials of, 89t
- PD-L1 ligand, PD-1/B7-H1/B7-DC pathway and, 245
- PD-L2 ligand, PD-1/B7-H1/B7-DC pathway and, 245
- Pentavalent vaccines, evaluation of, 24, 25
- Peptide antigens, in antigen-specific therapy, 6–7
- Peptide-based vaccines, 69–71
  - with antigen-presenting cells, 81
  - characteristics of, 82t
  - clinical trials of, 88–89t
  - CTL peptide target identification and, 69–70
  - for treatment of human diseases, 70–71
  - vehicles for delivery of, 70
- Peptide–MHC complex
  - immune-response induction and, 100
  - interactions with T cell receptors, 244
- Peptide motifs, in antigen-specific therapy, 6
- Percutaneous BCG, 32
  - in prostate cancer treatment, 36
- Perforin, in ELISpot assay, 276
- Peripheral blood mononuclear cells (PBMCs)
  - in ELISpot assay, 276
  - in flow cytometry, 278
  - PD-1 gene and, 245
  - in polyepitope technology, 71
  - in tetramer analysis, 277
- PEST (proline, glutamic acid, serine, threonine)-like domains, 117
- Phagocytes, *Listeria monocytogenes* and, 114–116
- Phagocytic receptors, in yeast-based immunotherapy, 132, 133
- Phagocytosis
  - in BCG treatment, 37
  - of yeast cells, 132, 133
- Phase II trials, xiv
- Phase III trials, xiv, xv
- Phenotype changes, in vaccine monitoring, 294
- Phenotypic assays, in cancer vaccine evaluation, 297
- Phorbol myristate acetate (PMA), CD137 and, 253–254
- Phosphorothioate (PS) ODN, CpG-specific responses to, 44
- Phytohemagglutinin (PHA), CD137 and, 253
- Plasmacytoid dendritic cells (pDCs)
  - contamination by, 45
  - CpG ODNs in stimulating, 47–48, 53
  - Treg interactions with, 194, 195
- Plasmid copy number, in yeast-based vaccine vector design, 139–141
- Plasmid DNA, in treating HPV, 80
- Plasmid DNA vectors, in antigen-specific therapy, 6
- Plasmid release, *Listeria monocytogenes* and, 119–121
- Pluripotential transcription factor (PrfA), *Listeria monocytogenes* and, 116, 119–120
- Polyepitope vaccines, 69–78
  - in antigen-specific therapy, 6
  - clinical studies of, 75–77
  - peptide-based, 69–71
  - technology of, 71–72, 74t, 76
  - in treatment of EBV-associated malignancies, 73–75, 76
- PolyG motifs/sequences
  - in activating TLR9, 45
  - in immune stimulatory CpG ODNs, 46
- Polymerase chain reactions (PCRs), 121, 279
- “Polyvalent” approach, whole-tumor cells in, 153, 154
- Polyvalent vaccines, 22–23, 160
- Positron emission tomography (PET), in vivo imaging via, 283, 284
- Posttransplant lymphoproliferative disease (PTLD), treatment of EBV-associated malignancies and, 73
- Poxvirus vectors, 95–111
  - in combination therapies, 102–104
  - cytokine expression and, 101–102
  - history of cancer-therapy viral vectors and, 95–97, 106
  - modified vaccinia Ankara, 104–106
  - tumor-associated antigens and, 97–101
- Preclinical services, for vaccine production support, 293t
- Preclinical studies
  - of cancer vaccines, xiii, xv
  - of yeast-based immunotherapeutics, 144–145
- Prime-boost vaccines
  - clinical trials of, 90t
  - strategies for, xv
- Primed T cell transfer, in cancer treatment, 218
- Priming. *See also* Cross-priming
  - CD137 and, 255, 256
  - of poxvirus vaccines, 100
  - of tumor-specific T cells, 230, 233
- Progesterone receptor (PR), in monoclonal antibody therapy, 174

- Promoters, in yeast-based vaccine vector design, 139, 141–142
- Prostate cancer  
 allogeneic vaccines and, 155, 160  
 allogeneic whole-cell vaccines versus, 153  
 bacillus Calmette–Guérin in treatment of, 36–37  
 in endocrine therapy, 175  
 globo-H-KLH conjugate and, 18–19
- Prostate-specific antigen (PSA), 96  
 in antigen-specific therapy, 6, 97  
 in combination therapies, 103, 104  
 globo-H-KLH conjugate and, 19
- Protein antigens, in antigen-specific therapy, 6–7
- Protein-based vaccines  
 with antigen-presenting cells, 81  
 characteristics of, 82t  
 clinical trials of, 89t
- Proteins  
 in enhancing DC–T cell interaction, 86  
 in increasing antigen-expressing DCs, 82
- Proteomics analysis, in immune monitoring, 274t, 281
- PSAV marker, allogeneic vaccines and, 156  
*Pseudomonas aeruginosa* exotoxin A, in enhancing DC antigen expression, 84, 85
- PSMA proteins, in yeast-based immunotherapy, 135
- Purified protein derivative (PPD) skin test, bacillus Calmette–Guérin and, 32
- Q61L mutation, yeast-based immunotherapy and, 136–137, 138
- Q61R mutation, yeast-based immunotherapy and, 136–137, 138
- QA/QC (quality assurance/quality control) program, assay quality and, 293t, 295, 301–303, 304
- Quantitative reverse transcriptase [real time] polymerase chain reaction (qRT-PCR), in immune monitoring, 273, 274t, 279–280
- Radiation therapy (radiotherapy)  
 immunotherapy and, 9, 10  
 poxvirus vectors in combination with, 102–103
- RA-HPV vaccine, clinical trials of, 90t
- Raloxifene, in endocrine therapy, 174
- Randomized trials, xiv–xv
- Ras proteins, in yeast-based immunotherapy, 135–137
- RastaFAR GI-4000 yeast strain, 138
- Rat prostate cancer, allogeneic vaccines and, 155
- Rb-binding protein, human papillomavirus and, 117
- RECIST (response evaluation criteria in solid tumors) criteria, xi–xv
- Recombinant antigen expression, in bacteria, 121
- Recombinant cytokines, 158
- Recombinant fowlpox virus expressing CEA (rF-CEA)  
 immune-response induction and, 101  
 with MVA, 104–105
- Recombinant fowlpox virus expressing PSA (rF-PSA), in combination therapies, 103
- Recombinant nonpathogenic brewer's yeast, in immunotherapy, 131–132, 145–147. *See also Saccharomyces cerevisiae*
- Recombinant vaccine vectors, 114–122
- Recombinant vaccinia virus expressing CEA (rV-CEA)  
 boosts for, 100  
 in clinical trials, 97, 98t  
 in combination therapies, 102–103  
 immune-response induction and, 101  
 with MVA, 104–105  
 poxvirus vectors and, 102
- Recombinant vaccinia virus expressing PSA (rV-PSA)  
 in clinical trials, 97, 99t  
 in combination therapies, 103
- Recombinase activating gene (BAG), PD-1/B7-H1/B7-DC pathway and, 246
- Regulation, of vaccine production, 293–294
- Regulatory T cells (Tregs). *See also* Regulatory T lymphocytes; T-regulatory (Treg) activity; T-regulatory cells (Tregs)  
 antitumor immunity and, xiii  
 in cancer immunity suppression, 211–212, 213  
 in cancer vaccine objectives, 295  
 in chemotherapy-modulated immune tolerance, 171–172  
 CpG ODNs and TLR9 in stimulating, 48–49  
 GM-CSF-secreting vaccines and, 177  
 in immune-based therapies, 179–180  
 in immune monitoring, 272–273
- Regulatory T lymphocytes, 190
- Renal cancer, bacillus Calmette–Guérin in treatment of, 36
- Renal cell carcinoma (RCC)  
 bacillus Calmette–Guérin in treatment of, 36  
 cytokines versus, 157–158  
 TroVax and MVA versus, 106
- Repressible promoters, in yeast-based vaccine vector design, 141, 142
- Reverse signaling, PD-1/B7-H1/B7-DC pathway and, 248

- Rheostatic promoters, in yeast-based vaccine vector design, 141, 142
- RNA, in qRT-PCR, 280. *See also* mRNA
- RNA-based vaccines, characteristics of, 82t
- RNA viruses, as cancer-therapy vaccine vectors, 96
- Route of administration, in yeast-based immunotherapy, 143–144
- Rüter, Jens, xi, 189
- Saccharides, as adjuvants, 5
- Saccharomyces cerevisiae*, in antigen-specific therapy, 7, 131–149
- Safety factors
- CpG ODN, 53–54
  - of DNA-based vaccines, 91
  - of vaccine vectors, 114, 122–123
  - in yeast-based immunotherapy, 144–145
- Salmonella*, as bacterial vaccine vector, 114, 116
- Scavenger receptors, in activating TLR9, 45
- Schlom, Jeffrey, xi, xiii
- Secondary lymphoid structure, organogenesis of, 232
- Secondary lymphoid tissue chemokine (SLC, CCL21), in creating tumor lymphoid tissue, 232
- L-Selectin<sup>+</sup> naive T cells, in creating tumor lymphoid tissue, 232
- Selective estrogen receptor destroyers (SERDs), breast tumor immunity and, 174
- Selective estrogen receptor modulators (SERMs), breast tumor immunity and, 174
- Self-antigens
- polyepitope technology and, 72
  - in yeast-based immunotherapy, 135, 143
- Self-proteins, in yeast-based immunotherapy, 135
- Semliki forest virus, as cancer-therapy vaccine vector, 96
- Serial monitoring, of vaccine administration, 294, 296
- Serial specimens, quality assurance/quality control for, 302
- Services, for vaccine production support, 292, 293t
- SGN-00101 vaccine, clinical trials of, 89t
- Sheep, safety of CpG ODN in, 53
- Shigella*, as bacterial vaccine vector, 114, 116
- Short interfering RNA (siRNA), in enhancing DC–T cell interaction, 86
- SHP-2 cytoplasmic tyrosine phosphatase, PD-1/B7-H1/B7-DC pathway and, 245
- Shuttle plasmids, 120–121
- Simulect, versus CD25, 191
- Sindbis virus, as cancer-therapy vaccine vector, 96
- Single-cell assays, in cancer vaccine evaluation, 297, 298, 300
- Single-chain trimer (SCT) technology, enhancing DC antigen expression via, 84
- SKBR3 cell line, 178
- Skin tests, in cancer vaccine evaluation, 300–301
- Small cell lung cancer (SCLC) cells, fucosyl-GM1–KLH conjugate and, 20
- Small peptide epitopes, CTL peptide target identification and, 69–70
- Smallpox, 243
- eradication of, 97
- Smith, Corey, xi, 69
- Solid tumors, 169. *See also* Cancer entries; Tumor entries
- adaptive immune rejection of, 51–52
  - structure of, 230
  - treatment of, 217
- Souders, Nicholas C., xi, 113
- Southwest Oncology study, of BCG, 33
- Species-specific TLR9 expression, 44–45
- Specific assays, in cancer vaccine evaluation, 297
- Specimen batching, in cancer vaccine evaluation, 298
- Specimen collection, in vaccine monitoring, 294. *See also* Human specimens
- Speiser, Daniel E., xi, 43
- Spleen
- cancer immunity suppression and, 211, 212
  - in constructing *Listeria* vaccine vectors, 121
  - syngeneic HSCT and, 207, 208
- Splenic Gr1<sup>+</sup> immature myeloid cells, tumors and, 234–235
- Splenic T cells, CD137 and, 255
- Splenocytes
- cancer immunity suppression and, 211, 212, 213
  - in CD137 studies, 257
  - syngeneic HSCT and, 207, 208, 209, 210
- Splenomegaly, 234–235
- Sportes, Claude, xi, 217
- Spot-forming units (SFUs), in ELISpot assay, 275
- Squamous cell carcinoma of the head and neck (SCCHN), in tetramer analysis, 277
- Standard-dose chemotherapy, breast tumor vaccines and, 171
- Standardization
- of assays, 284–285
  - quality assurance/quality control for, 302–303
  - in vaccine evaluation, 292

- Standard operating procedure (SOP)  
 quality assurance/quality control in, 303  
 vaccine production and, 294
- Staphylococcal enterotoxin A (SEA), CD137  
 and, 255
- Stem cells. *See* Hematopoietic stem cell  
 transplantation (HSCT)
- Stereocenters, oligosaccharide synthesis and, 17
- Stimulation index (SI), in T cell proliferation  
 assays, 282
- STn antigen, in pentavalent vaccine, 24, 25
- Strategies, for activating antitumor response,  
 xiii–xiv, xv, xvi. *See also* Monitoring  
 strategies
- Stroma, as immunologic barrier, 230, 231
- Stroma-derived factor 1 (SDF1), ovarian cancer  
 and, 194
- Stromal cells, in creating tumor lymphoid tissue,  
 232–234
- Suppressor cells, antitumor immunity and, xiii
- Surface antigens, in pDC depletion, 195
- Synergistic effects  
 in breast cancer treatment, 170  
 with CpG ODNs, 50
- Syngeneic HSCT, 206–210  
 cancer immunity suppression and, 211
- Synthetic antitumor vaccines,  
 carbohydrate-based, 15–27
- Synthetic phosphorothioate (PS) ODN,  
 CpG-specific responses to, 44
- T47D cell line, 178
- TAA-reactive Tregs, 190
- TAA-specific immunity, 190. *See also*  
 Tumor-associated antigens (TAAs)
- TAA-specific Tregs, tumor vaccines versus,  
 196–197, 198
- TA-CIN vaccine, clinical trials of, 90t
- TA-HPV vaccine, clinical trials of, 88t
- Tamoxifen, 169  
 in endocrine therapy, 174
- Target antigens, tolerance and, 223–224
- Targeted assays, in cancer vaccine evaluation,  
 297, 304
- Tarmogens™ (targeted molecular immunogens),  
 in immunotherapy, 131–132, 139,  
 145–147. *See also* *Saccharomyces*  
*cerevisiae*
- T cell assays, 273–274, 282–283
- T-cell-depleting nonmyeloablative chemotherapy,  
 immunotherapy and, 9
- T cell depletion, outside high-dose  
 chemotherapy, 219–220
- T-cell-independent humoral response, 16
- T cell leukemia, CD137 and, 253
- T cell proliferation assay, in immune monitoring,  
 282
- T-cell receptor recognition, in cancer vaccine  
 evaluation, 298, 299
- T cell receptors (TCRs), MHC–peptide complex  
 and, 244
- T cell reconstitution  
 following autologous HSCT, 206–210  
 following HSCT, 220–223  
 optimizing, 223
- T cell responses  
 cancer vaccines and, 43, 44  
 to whole-cell vaccines, 154  
 in yeast-based immunotherapy, 143–144, 146
- T cells. *See also* Activated T cells; Effector T  
 cells; T lymphocytes; Tumor-specific T cells  
 in adaptive-immune solid-tumor rejection,  
 51–52  
 in antigen-specific cancer immunotherapy,  
 79–80, 81  
 bacterial vaccine vectors and, 114  
 breast tumor vaccines and, 171  
 cancer immunotherapy strategies and,  
 231–232  
 in cancer treatment, 218  
 in cancer vaccine evaluation, 298–299, 300,  
 304  
 in cancer vaccine objectives, 295  
 carcinogenesis and, 229  
 CD137 in, 255–256, 256–257  
 CD137 mRNA in, 253–254  
 in CD137 studies, 260  
 in chemotherapy-modulated immune tolerance,  
 171–172  
 in combination therapies, 103, 104  
 costimulatory and coinhibitory molecules and,  
 244  
 CpG ODNs in stimulating, 47  
 in creating tumor lymphoid tissue, 232–234  
 in cytotoxic assays, 282  
 efficient activation of, 53  
 in ELISpot assay, 274–276  
 ex vivo investigations of, 52–53  
 in flow cytometry, 278–279  
 HER2/*neu*-specific, 176  
 in immune monitoring, 273  
 inside tumors, 234, 237  
 interleukin 2 and, xiv  
*Listeria monocytogenes* and, 115  
 LMP polyepitopes and, 74, 75, 76  
 PD-1/B7-H1/B7-DC pathway and, 246, 247,  
 248, 250, 251  
 PD-1 expression on, 246

- in poxvirus clinical trials, 97
- in qRT-PCR, 279–280
- as sensitive immune stimulation detectors, 52
- strategies for increasing DC interaction with, 86, 87
- in tetramer analysis, 276–277
- vaccine activation of, xiii
- yeast-based immunotherapy and, 132, 134
- T cell signaling, 244
- T cell transfer therapy, as cancer immunotherapy strategy, 230–231
- T cell vaccination, 52
- Technology, of polyepitope vaccines, 71–72, 74t, 76
- TEF1* (translation elongation factor 1) promoter, in yeast-based vaccine vector design, 142
- TEF2* (translation elongation factor 2) promoter, in yeast-based vaccine vector design, 142
- Temperature control, quality assurance/quality control for, 302
- Tertiary lymphoid structure (TLS)
  - cancer immunotherapy strategies and, 231–232
  - formation of, 232, 233
- Tetramer analysis
  - in cancer vaccine evaluation, 298, 299
  - in immune monitoring, 273, 274t, 276–278
- Tetramers, 276
- Tf(c)-KLH clusters. *See also* Keyhole limpet hemocyanin (KLH)
  - clustered vaccines and, 21–22
  - in pentavalent vaccine, 24, 25
- Th1-like immune response, 43, 44
  - CpG ODNs in stimulating, 47
  - innate immune system and, 49
  - in mouse tumor models, 51
  - in yeast-based immunotherapy, 146
- Th2-like immune response, 44
  - innate immune system and, 49
- T helper (Th) epitope, in enhancing DC antigen presentation, 85–86
- T helper immunity, in chemotherapy-modulated immune tolerance, 171–172
- Therapeutic HPV vaccine clinical trials, 88–90t
- THF $\alpha$  receptor-activated factor-6 (TRAF6), CpG ODNs in stimulating, 47
- Thiotepa, BCG versus, 32t, 35
- Thymic apoptosis, PD-1 gene and, 245. *See also* Apoptosis
- Thymic reconstitution
  - enhancing, 223, 224
  - following autologous HSCT, 206–207
- Thymopoiesis, in T cell regeneration, 221
- Thymus
  - cancer immunity suppression and, 211
  - PD-1 gene and, 245
  - syngeneic HSCT and, 206, 207
  - in T cell regeneration, 221
- Tissue handling, vaccine production and, 293
- Tissue samples, quality assurance/quality control for, 302
- TLR9 agonists, 52–53
  - safety of CpG ODN and, 54
- TLR ligation, 193
- TLR signaling, versus Tregs, 193. *See also* Toll-like receptor entries
- T lymphocyte activity, antitumor, 218
- T lymphocytes. *See also* T cell entries
  - cancer immunotherapy strategies and, 231–232
  - in cancer vaccine evaluation, 299
  - immunotherapy and, 10
  - in tetramer analysis, 276
- Tn(c)-KLH clusters. *See also* Keyhole limpet hemocyanin (KLH)
  - clustered vaccines and, 21–22
  - in pentavalent vaccine, 24, 25
  - in trivalent vaccine, 23
- TNFR1 receptor, in creating tumor lymphoid tissue, 232
- TNF-related apoptosis-inducing ligand (TRAIL). *See also* Tumor necrosis factor entries
  - in BCG treatment, 37
  - CpG ODNs in stimulating, 47
  - in stimulating innate and adaptive immunity, 47
- TNF-secreting CTLs, 177
- TNF/TNFR (tumor necrosis factor/receptor) protein superfamily, 253
- Tolerance, target antigens and, 223–224
- Tolerogenic dendritic cells, 196
- Toll-like receptor 8 (TLR8), regulatory T cells and, 48
- Toll-like receptor 9 (TLR9), 43–66
  - activation and expression of, 44–46
  - history of, 43–44
  - safety of CpG ODN and, 54
- Toll-like receptor ligands, in adjuvants, 5–6
- Toll-like receptors (TLRs), 43–44
  - versus Tregs, 193
  - in yeast-based immunotherapy, 132, 133
- Total-body irradiation (TBI), conditioning with, 206, 207, 208, 209
- Toxicity, of BCG, 37–38. *See also* Cytotoxic entries; Lymphotoxin entries
- Transferrin receptor (TfR), in enhancing DC antigen expression, 85

- Transforming growth factor  $\beta 1$  (TGF $\beta 1$ ), inside tumors, 234
- Transgenic mice, CD137L studies in, 257
- Transplantation. *See* Bone marrow transplantation; Hematopoietic stem cell transplantation (HSCT)
- Trastuzumab
  - breast cancer treatment with, 169–170
  - in monoclonal antibody therapy, 173–174
- Treg blockade, in immune monitoring, 273
- Treg trafficking blockade, 194
- T-regulatory (Treg) activity
  - immunotherapy and, 8–9, 159
  - in tumor immunotherapy, 189–204
- T-regulatory cells (Tregs), 190. *See also* Regulatory T cells (Tregs)
  - anti-CTLA4 antibodies and, 193
  - chemokine signaling versus, 194
  - depletion of, 190–192
  - functional blockade of, 192–194
  - interactions with other cells, 194–196
  - manipulation of, 189–204
  - suppressing functions of, 190
  - suppression of effector CD4<sup>+</sup> and CD8<sup>+</sup> T cells by, 190
  - tumor vaccines versus, 196–197
  - vascular leukocytes versus, 196
- Trials. *See* Clinical trials
- TRICOM (triad of costimulatory molecules)
  - vectors. *See also* B7–1 costimulatory molecule; Intercellular adhesion molecule 1 (ICAM-1); Leukocyte function-associated antigen 3 (LFA-3)
  - in antigen-specific therapy, 6–7, 98t, 100–101
  - in combination therapies, 102–103, 104
  - with MVA, 104–105
  - poxvirus vectors and, 102
- Trivalent vaccines, evaluation of, 23
- TroVax, with MVA, 105–106
- Tsen, Shaw-Wei D., xi, 79
- Tuberculosis, bacillus Calmette–Guérin in
  - treatment of, 29, 30
- Tumor antigen exposure, in cancer treatment, 218
- Tumor antigens
  - allogeneic whole-cell vaccines and, 153
  - in immune monitoring, 271
  - in yeast-based immunotherapy, 135, 138–139
- Tumor-associated antigens (TAAs), xv
  - adenovirus-encoding, 95–96
  - in cancer vaccine objectives, 295–296
  - in CD137 studies, 258
  - in combination therapies, 102, 103
  - immune response to, 189–190
  - in polyvalent vaccines, 22
  - poxvirus vectors and, 97–101
  - vaccine production and, 293
- Tumor-associated carbohydrate antigens, 16
- Tumor-associated macrophages (TAMs), tumors and, 235
- Tumor-associated oligosaccharides, 16
- Tumor burden
  - in cancer treatment, 218
  - cancer vaccines and, 212–213
  - HCST and, 218–219
- Tumor cell antigen escape variants, xiv
- Tumor-cell-based vaccines, characteristics of, 82t
- Tumor cells
  - in cancer immunotherapy, 7–10
  - CD137L on, 254
  - cytokine-secreting, 158
  - immune system versus, 15–16
  - Listeria monocytogenes* versus, 116
  - modified whole-cell vaccines and, 156–157
  - surface carbohydrates of, 15–16
- Tumor cell-surface expression, heterogeneity of, 22, 23
- Tumor challenge models, in yeast-based immunotherapy, 134–135
- Tumor development, 4
- Tumor-draining lymph node (TDLN) T cells, in CD137 studies, 260, 261
- Tumor elimination
  - as cancer vaccine objective, 295
  - in vaccine evaluation, 291
- Tumor immunity
  - in breast cancer treatment, 170–173
  - jump-starting with breast cancer therapeutics, 169–187
- Tumor immunology, in antigen-specific cancer immunotherapy, 79
- Tumor immunosurveillance, 4
- Tumor immunotherapy, 189–190
  - T-regulatory cell manipulation in, 189–204
- Tumor-infiltrating lymphocytes (TILs)
  - breast tumor vaccines and, 171
  - in cancer immunotherapy strategies, 231
- Tumor microenvironment, chemotherapy and, 173
- Tumor microenvironmental Tregs, 190
- Tumor necrosis factor alpha (TNF $\alpha$ )
  - BCG immune response and, 37
  - in flow cytometry, 278
  - Listeria monocytogenes* and, 115, 116
  - PD-1/B7-H1/B7-DC pathway and, 248, 250
  - in T cell activation, 53
  - in yeast-based immunotherapy, 146
- Tumor necrosis factors (TNFs), in creating tumor lymphoid tissue, 232

- Tumor recurrence, after BCG treatment 34–35
- Tumor regression, antigen-specific T cells and, 231
- Tumor rejection, in vaccine evaluation, 291–292
- Tumor removal, immunotherapy and, 9–10
- Tumors. *See also* Cancer entries; Solid tumors
- adaptive immune rejection of, 51–52
  - allogeneic vaccines and, 155
  - antigenic heterogeneity of, xiv
  - changing environment inside, 235, 237
  - costimulatory and coinhibitory molecules and, 244
  - immune system and, 3, 4
  - immunosuppressive environment inside, 234–235
  - internal environment of, 232–236
  - Listeria monocytogenes* versus, 116
  - tumor immunotherapy versus, 189–190
- Tumor size, in clinical activity valuation, xiv
- Tumor-specific T cells
- carcinogenesis and, 229
  - priming of, 230
- Tumor-specific vaccines, in cancer treatment, 217–218
- Tumor survival, in vaccine evaluation, 291
- Tumor vaccines
- breast cancer chemotherapy and, 171
  - breast cancer treatment with, 170
  - versus Tregs, 196–197
- Unimolecular monovalent vaccines, 18–20
- Unimolecular multivalent vaccines, 23–25
- United States, BCG treatment in, 38. *See also*
- American Urological Association (AUA) guidelines; College of American Pathologists (CAP); Food and Drug Administration (FDA)
- Unmethylated CpG dinucleotides, TLR9 in detecting, 44
- Urethane-induced tumors
- yeast-based immunotherapy and, 136–137
  - yeast-based vaccine vector design and, 139
- VAAA vaccinations, 100
- Vaccination. *See also* Vaccine entries
- enhancing by stimulating TLR9, 43–66
  - following HSCT, 206
  - history of, 243–244
- Vaccination therapies, tools necessary to support, 292–295
- Vaccine efficacy, in yeast-based immunotherapy, 146–147
- Vaccine monitoring, 293t
- quality assurance/quality control for, 302–303
- Vaccine preparation, 293t
- Vaccine production, regulation of, 293–294
- Vaccines. *See also* Bacillus Calmette–Guérin (BCG); Breast cancer vaccines; Cancer vaccines; Experimental vaccine development; Peptide-based vaccines; Polyepitope vaccines; Tumor vaccines; Viral vector-based vaccines; Whole-cell vaccines
- clustered, 20–22
  - CpG ODNs as adjuvants for, 49
  - hematopoietic stem cell transplantation and, 217–228
  - in cancer therapy, xiii, 95, 205–206
  - polyepitope, 69–78
  - polyvalent, 22–23, 160
  - strategies for, 223–224
  - unimolecular monovalent, 18–20
  - unimolecular multivalent, 23–25
  - using *Listeria monocytogenes*, 113–129
- Vaccine vectors. *See also* Vaccinia virus (VV) vectors; Viral vector-based vaccines
- constructing from *Listeria monocytogenes*, 119–122
  - live recombinant, 114–122
  - safety of, 114, 122–123
- Vaccinia virus (VV) vectors
- in antigen-specific therapy, 6–7
  - applications of, 97–106
  - in polyepitope technology, 71, 72
- Vascular endothelial growth factor (VEGF), in monoclonal antibody therapy, 174
- Vascular leukocytes, versus Tregs, 196
- VaxImmune™, CpG ODNs used with, 50
- Venezuelan equine encephalitis virus, as cancer-therapy vaccine vector, 96
- Verch, Thorsten, xi, 113
- Viral vector-based vaccines. *See also* Poxviral vectors; Vaccinia virus (VV) vectors
- clinical trials of, 87
  - safety concerns related to, 123
- Virulence factors, *Listeria monocytogenes* and, 116
- Viruses, as vaccine vectors, 114
- Virus-like particle (VLP) vaccines, in immune monitoring, 272
- Vitamins, with BCG treatment, 35
- VP22 viral proteins, in increasing antigen-expressing DCs, 82
- Wansley, Elizabeth K, xi, 95
- Whiteside, Theresa L., xi, 291
- Whole-body imaging, 283–284
- Whole-cell vaccines
- advantages of, 154–155

- Whole-cell vaccines (*Continued*)  
allogeneic, 153–157  
effectiveness of, 155–156  
future research in, 159–160  
modification to secrete cytokines, 157–159  
modification with costimulatory molecules,  
156–157  
T cell responses elicited by, 154  
Wild-type (WT) K1736 tumor, in CD137 studies,  
257  
Wilson, Rebecca M., xi, 15  
Wu, T.-C., xi, 79
- Xenogeneic APCs, in ELISpot assay, 275
- Yeast-based immunotherapy  
clinical trials in, 144, 145  
coupling innate and adaptive immunity with,  
131–149  
dose-response parameters in, 143–144  
molecular mechanisms of action in, 132–135  
mutated Ras and therapeutic animal models  
for, 135–137  
preclinical safety studies in, 144–145  
yeast-based vaccine vector design in, 139–144  
yeast-expressed tumor-antigens in, 138–139
- Yeast “cocktail,” 132, 146
- Yeast-delivering tumor antigens, 132
- Yeast-expressed tumor antigens, 138–139
- Yeast expressing chicken ovalbumin (OVAX), in  
yeast-based immunotherapy, 133–134,  
134–135
- Yeast lacking foreign antigens (YVEC), in  
yeast-based immunotherapy, 133–134,  
135
- Yeast number, in yeast-based immunotherapy,  
143
- Yu, Ping, xi, 229
- Zenapax, versus CD25, 191
- Zeta-chain expression, in tetramer analysis,  
277
- Zou, Weiping, xi, 189
- ZYC-101 microencapsulated DNA-based  
vaccines, human clinical trials of, 86–87,  
89t